https://trial.medpath.com/news/promis-neurosciences-reports-interim-phase-1b-data-for-pmn310-showing-strong-safety-and-biomarker-signals 2026-09-09T15:30:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promis-neurosciences-reports-interim-phase-1b-data-for-pmn310-showing-strong-safety-and-biomarker-signals 2026-09-09T15:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/panntherapi-receives-french-ansm-nod-to-advance-pti5803-into-phase-2a-trial 2026-09-09T15:30:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panntherapi-receives-french-ansm-nod-to-advance-pti5803-into-phase-2a-trial 2026-09-09T15:30:19+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-s-symvess-shelf-life-extended-to-36-months-following-fda-authorization 2026-09-09T15:19:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humacyte-s-symvess-shelf-life-extended-to-36-months-following-fda-authorization 2026-09-09T15:19:21+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-del-desiran-misses-primary-endpoint-in-phase-3-harbor-rattling-dmpk-targeting-field 2026-09-09T15:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-del-desiran-misses-primary-endpoint-in-phase-3-harbor-rattling-dmpk-targeting-field 2026-09-09T15:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-decision-on-apitegromab-for-sma-expected-by-september-30 2026-09-09T15:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-decision-on-apitegromab-for-sma-expected-by-september-30 2026-09-09T15:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-s-emd-serono-acquires-postera-s-oral-fertility-programs-targeting-fshr-and-lhcgr 2026-09-09T14:51:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-s-emd-serono-acquires-postera-s-oral-fertility-programs-targeting-fshr-and-lhcgr 2026-09-09T14:51:03+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-acquires-mlm-medical-labs-creating-first-wholly-owned-central-lab-network-across-four-continents 2026-09-09T14:46:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-acquires-mlm-medical-labs-creating-first-wholly-owned-central-lab-network-across-four-continents 2026-09-09T14:46:41+00:00 hourly 0.9 https://trial.medpath.com/news/leyden-labs-advances-intranasal-rig-i-agonist-rig-101-to-rhinovirus-challenge-trial-after-phase-i-safety-and-biomarker-success 2026-09-09T14:40:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leyden-labs-advances-intranasal-rig-i-agonist-rig-101-to-rhinovirus-challenge-trial-after-phase-i-safety-and-biomarker-success 2026-09-09T14:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/merck-tests-adcs-alone-and-with-keytruda-across-breast-and-gynecologic-cancers 2026-09-09T14:38:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-tests-adcs-alone-and-with-keytruda-across-breast-and-gynecologic-cancers 2026-09-09T14:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-opens-182000-sq-ft-foster-city-research-hub-under-32bn-us-investment-programme 2026-09-09T14:23:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-opens-182000-sq-ft-foster-city-research-hub-under-32bn-us-investment-programme 2026-09-09T14:23:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-intellia-s-lonvo-z-an-in-vivo-crispr-therapy-for-hereditary-angioedema 2026-09-09T14:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-intellia-s-lonvo-z-an-in-vivo-crispr-therapy-for-hereditary-angioedema 2026-09-09T14:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-s-oral-infigratinib-shows-benefits-beyond-growth-in-phase-3-propel-3-achondroplasia-trial 2026-09-09T14:18:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-s-oral-infigratinib-shows-benefits-beyond-growth-in-phase-3-propel-3-achondroplasia-trial 2026-09-09T14:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/why-promising-compounds-still-fail-drug-discovery-shifts-toward-earlier-translatability-testing 2026-09-09T13:49:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/why-promising-compounds-still-fail-drug-discovery-shifts-toward-earlier-translatability-testing 2026-09-09T13:49:56+00:00 hourly 0.9 https://trial.medpath.com/news/revvity-to-acquire-human-cell-design-adding-human-pancreatic-beta-cell-models-for-metabolic-drug-discovery 2026-09-09T13:49:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revvity-to-acquire-human-cell-design-adding-human-pancreatic-beta-cell-models-for-metabolic-drug-discovery 2026-09-09T13:49:53+00:00 hourly 0.9 https://trial.medpath.com/news/evommune-s-oral-mrgprx2-antagonist-evo756-fails-phase-2b-in-atopic-dermatitis-program-halted 2026-09-09T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evommune-s-oral-mrgprx2-antagonist-evo756-fails-phase-2b-in-atopic-dermatitis-program-halted 2026-09-09T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharvaris-s-oral-deucrictibant-xr-cuts-hae-attack-rate-83-in-phase-iii-chapter-3 2026-09-09T13:38:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharvaris-s-oral-deucrictibant-xr-cuts-hae-attack-rate-83-in-phase-iii-chapter-3 2026-09-09T13:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/lancet-publishes-phase-1-data-for-pepromene-s-baff-r-car-t-80-complete-response-grade-1-only-toxicity 2026-09-09T13:38:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lancet-publishes-phase-1-data-for-pepromene-s-baff-r-car-t-80-complete-response-grade-1-only-toxicity 2026-09-09T13:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/rentosertib-shifts-six-proteomic-aging-clocks-in-phase-2a-ipf-substudy-but-cannot-separate-anti-aging-from-anti-fibrotic-effects 2026-09-09T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rentosertib-shifts-six-proteomic-aging-clocks-in-phase-2a-ipf-substudy-but-cannot-separate-anti-aging-from-anti-fibrotic-effects 2026-09-09T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/compass-pathways-comp360-holds-13-point-madrs-benefit-at-52-weeks-in-phase-3-comp005-nda-submission-set-for-q4 2026-09-09T13:21:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-pathways-comp360-holds-13-point-madrs-benefit-at-52-weeks-in-phase-3-comp005-nda-submission-set-for-q4 2026-09-09T13:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-seeks-public-input-to-advance-development-of-botanical-drug-products 2026-09-09T13:19:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-seeks-public-input-to-advance-development-of-botanical-drug-products 2026-09-09T13:19:05+00:00 hourly 0.9 https://trial.medpath.com/news/opus-genetics-reports-positive-low-dose-cohort-1-data-for-opgx-best1-in-best1-related-retinal-diseases-aligns-with-fda-on-pivotal-endpoint 2026-09-09T13:18:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opus-genetics-reports-positive-low-dose-cohort-1-data-for-opgx-best1-in-best1-related-retinal-diseases-aligns-with-fda-on-pivotal-endpoint 2026-09-09T13:18:15+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-voxzogo-hits-primary-endpoint-in-phase-3-hypochondroplasia-trial-published-in-nejm-evidence 2026-09-09T13:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-s-voxzogo-hits-primary-endpoint-in-phase-3-hypochondroplasia-trial-published-in-nejm-evidence 2026-09-09T13:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-s-ersodetug-phase-3-sunrize-misses-primary-endpoint-in-congenital-hyperinsulinism-fda-review-continues 2026-09-09T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezolute-s-ersodetug-phase-3-sunrize-misses-primary-endpoint-in-congenital-hyperinsulinism-fda-review-continues 2026-09-09T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/nejm-publishes-phase-3-data-for-takeda-s-oveporexton-the-first-approved-orexin-agonist-for-narcolepsy-type-1 2026-09-09T12:27:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nejm-publishes-phase-3-data-for-takeda-s-oveporexton-the-first-approved-orexin-agonist-for-narcolepsy-type-1 2026-09-09T12:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/solstice-oncology-launches-with-225m-series-a-to-advance-next-generation-ctla-4-antibody-porustobart-in-neoadjuvant-colon-cancer 2026-09-09T12:20:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solstice-oncology-launches-with-225m-series-a-to-advance-next-generation-ctla-4-antibody-porustobart-in-neoadjuvant-colon-cancer 2026-09-09T12:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-spins-out-caspian-therapeutics-with-50m-to-develop-menin-inhibitors-for-diabetes 2026-09-09T12:19:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-spins-out-caspian-therapeutics-with-50m-to-develop-menin-inhibitors-for-diabetes 2026-09-09T12:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/bms-gprc5d-car-t-arlo-cel-hits-primary-endpoint-in-quadruple-class-exposed-multiple-myeloma 2026-09-09T12:18:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-gprc5d-car-t-arlo-cel-hits-primary-endpoint-in-quadruple-class-exposed-multiple-myeloma 2026-09-09T12:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/china-nmpa-accepts-marketing-authorization-application-for-hengrui-s-ripretinib-injection 2026-09-09T12:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-nmpa-accepts-marketing-authorization-application-for-hengrui-s-ripretinib-injection 2026-09-09T12:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-ucb-s-cimzia-certolizumab-pegol 2026-09-09T12:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-ucb-s-cimzia-certolizumab-pegol 2026-09-09T12:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-canada-finalizes-loi-with-pcpa-for-anzupgo-delgocitinib-cream-in-chronic-hand-eczema 2026-09-09T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-canada-finalizes-loi-with-pcpa-for-anzupgo-delgocitinib-cream-in-chronic-hand-eczema 2026-09-09T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-doses-first-participant-in-phase-1-study-of-ax-0811 2026-09-09T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proqr-doses-first-participant-in-phase-1-study-of-ax-0811 2026-09-09T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-launches-global-phase-ii-trial-of-girk4-inhibitor-bay-3670549-in-atrial-fibrillation 2026-09-09T11:42:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-launches-global-phase-ii-trial-of-girk4-inhibitor-bay-3670549-in-atrial-fibrillation 2026-09-09T11:42:41+00:00 hourly 0.9 https://trial.medpath.com/news/epilepsygtx-taps-viralgen-s-aava-platform-to-manufacture-aav-gene-therapy-epy201-ahead-of-first-in-human-trial 2026-09-09T11:26:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epilepsygtx-taps-viralgen-s-aava-platform-to-manufacture-aav-gene-therapy-epy201-ahead-of-first-in-human-trial 2026-09-09T11:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-camizestrant-for-esr1-mutant-hr-positive-her2-negative-breast-cancer-four-months-after-advisers-voted-no 2026-09-09T11:21:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-camizestrant-for-esr1-mutant-hr-positive-her2-negative-breast-cancer-four-months-after-advisers-voted-no 2026-09-09T11:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-starts-review-of-astrazeneca-s-copd-candidate 2026-09-09T11:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-starts-review-of-astrazeneca-s-copd-candidate 2026-09-09T11:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/pyxis-oncology-s-micvo-posts-36-confirmed-orr-and-79-12-month-os-probability-in-2l-r-m-head-and-neck-cancer 2026-09-09T11:14:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyxis-oncology-s-micvo-posts-36-confirmed-orr-and-79-12-month-os-probability-in-2l-r-m-head-and-neck-cancer 2026-09-09T11:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-nanoscope-s-bla-for-mogenry-an-optogenetic-gene-therapy-for-severe-vision-loss-in-retinitis-pigmentosa 2026-09-09T11:12:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-nanoscope-s-bla-for-mogenry-an-optogenetic-gene-therapy-for-severe-vision-loss-in-retinitis-pigmentosa 2026-09-09T11:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/tozorakimab-cuts-copd-exacerbations-by-up-to-34-in-two-phase-3-trials-fda-sets-q1-2027-decision 2026-09-09T11:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tozorakimab-cuts-copd-exacerbations-by-up-to-34-in-two-phase-3-trials-fda-sets-q1-2027-decision 2026-09-09T11:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-therapeutics-completes-enrollment-in-phase-1-2-start-001-monotherapy-cohorts-for-invikafusp-alfa-in-pd-1-resistant-solid-tumors 2026-09-09T11:02:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-therapeutics-completes-enrollment-in-phase-1-2-start-001-monotherapy-cohorts-for-invikafusp-alfa-in-pd-1-resistant-solid-tumors 2026-09-09T11:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/tyra-s-oral-fgfr3-inhibitor-dabogratinib-hits-100-orr-in-single-lesion-nmibc-but-phase-2-data-miss-street-bar 2026-09-09T11:01:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyra-s-oral-fgfr3-inhibitor-dabogratinib-hits-100-orr-in-single-lesion-nmibc-but-phase-2-data-miss-street-bar 2026-09-09T11:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-cimzia-for-preventing-adverse-pregnancy-outcomes-in-antiphospholipid-syndrome 2026-09-09T09:49:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-cimzia-for-preventing-adverse-pregnancy-outcomes-in-antiphospholipid-syndrome 2026-09-09T09:49:06+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-doses-first-patient-in-phase-2-sjogren-s-trial-of-vav1-degrader-mrt-6160-triggering-50m-payment-to-monte-rosa 2026-09-09T09:48:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-doses-first-patient-in-phase-2-sjogren-s-trial-of-vav1-degrader-mrt-6160-triggering-50m-payment-to-monte-rosa 2026-09-09T09:48:50+00:00 hourly 0.9 https://trial.medpath.com/news/jst-018-orthopoxvirus-antibody-cocktail-advances-into-first-in-human-phase-1-trial-under-u-s-department-of-war-program 2026-09-09T08:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jst-018-orthopoxvirus-antibody-cocktail-advances-into-first-in-human-phase-1-trial-under-u-s-department-of-war-program 2026-09-09T08:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/redasemtide-clears-ulcer-endpoint-in-dystrophic-eb-but-misses-primary-endpoint-in-global-phase-2-acute-ischemic-stroke-trial 2026-09-09T07:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redasemtide-clears-ulcer-endpoint-in-dystrophic-eb-but-misses-primary-endpoint-in-global-phase-2-acute-ischemic-stroke-trial 2026-09-09T07:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/western-australia-awards-775000-to-15-precision-medicine-projects-spanning-cancer-alzheimer-s-and-stroke 2026-09-09T06:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/western-australia-awards-775000-to-15-precision-medicine-projects-spanning-cancer-alzheimer-s-and-stroke 2026-09-09T06:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/rcp-review-finds-betrayal-of-trust-in-prolonged-temozolomide-prescribing-at-coventry-nhs-trust 2026-09-09T06:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rcp-review-finds-betrayal-of-trust-in-prolonged-temozolomide-prescribing-at-coventry-nhs-trust 2026-09-09T06:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/brandi-glanville-details-multidrug-resistant-infection-and-fungal-ball-diagnosis-ahead-of-surgery 2026-09-09T06:49:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brandi-glanville-details-multidrug-resistant-infection-and-fungal-ball-diagnosis-ahead-of-surgery 2026-09-09T06:49:23+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-riken-and-ibm-named-finalists-for-2026-acm-gordon-bell-prize-for-quantum-simulation-of-a-12635-atom-protein 2026-09-09T05:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-riken-and-ibm-named-finalists-for-2026-acm-gordon-bell-prize-for-quantum-simulation-of-a-12635-atom-protein 2026-09-09T05:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/forus-raises-150m-series-c-at-3b-valuation-to-scale-ai-network-for-medicine-access 2026-09-09T04:50:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forus-raises-150m-series-c-at-3b-valuation-to-scale-ai-network-for-medicine-access 2026-09-09T04:50:43+00:00 hourly 0.9 https://trial.medpath.com/news/hae-care-shifts-toward-attack-free-goals-as-experts-outline-when-to-reassess-treatment 2026-09-09T04:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hae-care-shifts-toward-attack-free-goals-as-experts-outline-when-to-reassess-treatment 2026-09-09T04:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fills-four-senior-leadership-roles-naming-permanent-directors-for-drugs-vaccines-and-tobacco 2026-09-09T03:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fills-four-senior-leadership-roles-naming-permanent-directors-for-drugs-vaccines-and-tobacco 2026-09-09T03:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/systematic-review-finds-very-low-certainty-evidence-for-hospital-based-interventions-linking-aud-patients-to-outpatient-care 2026-09-09T02:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systematic-review-finds-very-low-certainty-evidence-for-hospital-based-interventions-linking-aud-patients-to-outpatient-care 2026-09-09T02:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/inhibitor-therapeutics-advances-itraconazole-for-gorlin-syndrome-reports-0-265-new-surgically-eligible-bccs-per-patient-year 2026-09-08T23:52:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibitor-therapeutics-advances-itraconazole-for-gorlin-syndrome-reports-0-265-new-surgically-eligible-bccs-per-patient-year 2026-09-08T23:52:48+00:00 hourly 0.9 https://trial.medpath.com/news/rbqm-delivers-six-to-23-fold-return-on-investment-as-trial-complexity-becomes-the-new-normal 2026-09-08T23:52:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rbqm-delivers-six-to-23-fold-return-on-investment-as-trial-complexity-becomes-the-new-normal 2026-09-08T23:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/horien-wins-three-thai-fda-class-4-approvals-for-regenerative-devices-and-u-s-patent-for-biodegradable-ureteral-stent 2026-09-08T23:52:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/horien-wins-three-thai-fda-class-4-approvals-for-regenerative-devices-and-u-s-patent-for-biodegradable-ureteral-stent 2026-09-08T23:52:13+00:00 hourly 0.9 https://trial.medpath.com/news/texas-couple-sentenced-for-smuggling-unapproved-veterinary-drugs-and-pesticides-into-the-u-s 2026-09-08T22:56:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-couple-sentenced-for-smuggling-unapproved-veterinary-drugs-and-pesticides-into-the-u-s 2026-09-08T22:56:50+00:00 hourly 0.9 https://trial.medpath.com/news/family-calls-for-nhs-england-access-to-enhertu-after-woman-dies-of-breast-cancer-at-32 2026-09-08T18:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/family-calls-for-nhs-england-access-to-enhertu-after-woman-dies-of-breast-cancer-at-32 2026-09-08T18:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-ty1-reverses-systemic-sclerosis-effects-in-preclinical-study 2026-09-08T17:49:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-drug-ty1-reverses-systemic-sclerosis-effects-in-preclinical-study 2026-09-08T17:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/eppendorf-launches-refrigerated-centrifuge-5811-r-with-sustainable-r290-cooling 2026-09-08T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eppendorf-launches-refrigerated-centrifuge-5811-r-with-sustainable-r290-cooling 2026-09-08T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/west-virginia-reports-12-drop-in-drug-overdose-deaths-alongside-declines-in-violent-and-property-crime 2026-09-08T16:51:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/west-virginia-reports-12-drop-in-drug-overdose-deaths-alongside-declines-in-violent-and-property-crime 2026-09-08T16:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/scibase-receives-additional-order-from-castle-biosciences-to-accelerate-atopic-dermatitis-relapse-prediction-studies 2026-09-08T16:50:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scibase-receives-additional-order-from-castle-biosciences-to-accelerate-atopic-dermatitis-relapse-prediction-studies 2026-09-08T16:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/global-genes-partners-with-citizen-health-to-power-rare-x-rare-disease-data-platform 2026-09-08T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-genes-partners-with-citizen-health-to-power-rare-x-rare-disease-data-platform 2026-09-08T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-signs-exclusive-distribution-deal-with-akron-biotech-for-car-t-manufacturing-reagent-hcw11-006 2026-09-08T16:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcw-biologics-signs-exclusive-distribution-deal-with-akron-biotech-for-car-t-manufacturing-reagent-hcw11-006 2026-09-08T16:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/duane-a-mitchell-named-director-of-the-uf-health-cancer-institute 2026-09-08T15:50:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duane-a-mitchell-named-director-of-the-uf-health-cancer-institute 2026-09-08T15:50:24+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-ct-analysis-detects-significant-taladegib-treatment-effects-in-phase-2a-ipf-trial 2026-09-08T15:50:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-ct-analysis-detects-significant-taladegib-treatment-effects-in-phase-2a-ipf-trial 2026-09-08T15:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/me-therapeutics-advances-in-vivo-cd19-cd22-car-and-liver-detargeted-sting-mrna-programs 2026-09-08T15:49:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/me-therapeutics-advances-in-vivo-cd19-cd22-car-and-liver-detargeted-sting-mrna-programs 2026-09-08T15:49:59+00:00 hourly 0.9 https://trial.medpath.com/news/imdelltra-plus-imfinzi-delivers-landmark-overall-survival-benefit-in-first-line-extensive-stage-small-cell-lung-cancer 2026-09-08T14:51:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imdelltra-plus-imfinzi-delivers-landmark-overall-survival-benefit-in-first-line-extensive-stage-small-cell-lung-cancer 2026-09-08T14:51:03+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-acquires-mlm-medical-labs-becoming-the-only-central-lab-provider-with-a-wholly-owned-network-across-four-continents 2026-09-08T14:50:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-acquires-mlm-medical-labs-becoming-the-only-central-lab-provider-with-a-wholly-owned-network-across-four-continents 2026-09-08T14:50:52+00:00 hourly 0.9 https://trial.medpath.com/news/vapendavir-significantly-reduces-key-inflammatory-biomarkers-in-rhinovirus-challenged-copd-patients 2026-09-08T14:50:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vapendavir-significantly-reduces-key-inflammatory-biomarkers-in-rhinovirus-challenged-copd-patients 2026-09-08T14:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/orphalan-initiates-global-phase-3-traditional-study-of-once-daily-trientine-in-wilson-disease 2026-09-08T14:50:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orphalan-initiates-global-phase-3-traditional-study-of-once-daily-trientine-in-wilson-disease 2026-09-08T14:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/maxwell-biosciences-mxb-22510-sc-receives-fda-qidp-designation-for-bacterial-and-fungal-pneumonia 2026-09-08T14:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxwell-biosciences-mxb-22510-sc-receives-fda-qidp-designation-for-bacterial-and-fungal-pneumonia 2026-09-08T14:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/scinai-ends-pc111-deal-redirects-capital-to-nanoab-platform-and-cdmo-growth 2026-09-08T14:49:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scinai-ends-pc111-deal-redirects-capital-to-nanoab-platform-and-cdmo-growth 2026-09-08T14:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/veru-advances-oral-sabizabulin-after-preclinical-data-show-potent-activity-in-daraxonrasib-resistant-pancreatic-cancer 2026-09-08T13:51:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veru-advances-oral-sabizabulin-after-preclinical-data-show-potent-activity-in-daraxonrasib-resistant-pancreatic-cancer 2026-09-08T13:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/moonwalk-biosciences-closes-70m-series-b-to-advance-adipose-targeted-rnai-for-obesity 2026-09-08T13:50:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonwalk-biosciences-closes-70m-series-b-to-advance-adipose-targeted-rnai-for-obesity 2026-09-08T13:50:48+00:00 hourly 0.9 https://trial.medpath.com/news/accro-bioscience-announces-nmpa-clearance-for-phase-ii-iii-trial-of-ac-201-a-selective-tyk2-jak1-inhibitor-for-non-segmental-vitiligo 2026-09-08T13:49:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accro-bioscience-announces-nmpa-clearance-for-phase-ii-iii-trial-of-ac-201-a-selective-tyk2-jak1-inhibitor-for-non-segmental-vitiligo 2026-09-08T13:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/cloverleaf-bio-raises-33-million-seed-financing-to-advance-engineered-trna-cancer-therapeutics 2026-09-08T12:51:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cloverleaf-bio-raises-33-million-seed-financing-to-advance-engineered-trna-cancer-therapeutics 2026-09-08T12:51:33+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-reconsiders-coverage-of-dcisionrt-raising-stakes-for-precision-medicine-diagnostics 2026-09-08T12:51:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-reconsiders-coverage-of-dcisionrt-raising-stakes-for-precision-medicine-diagnostics 2026-09-08T12:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/welltrust-surpasses-100000-patient-consents-paving-the-way-for-ai-driven-clinical-trial-recruitment 2026-09-08T12:50:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/welltrust-surpasses-100000-patient-consents-paving-the-way-for-ai-driven-clinical-trial-recruitment 2026-09-08T12:50:45+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-to-present-phase-3-caplyta-data-across-bipolar-mania-depression-and-schizophrenia-at-psych-congress-2026 2026-09-08T12:50:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-to-present-phase-3-caplyta-data-across-bipolar-mania-depression-and-schizophrenia-at-psych-congress-2026 2026-09-08T12:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/kiora-pharmaceuticals-appoints-keith-j-lane-as-evp-of-global-clinical-development-and-regulatory-affairs 2026-09-08T12:49:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiora-pharmaceuticals-appoints-keith-j-lane-as-evp-of-global-clinical-development-and-regulatory-affairs 2026-09-08T12:49:38+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-publishes-preclinical-data-showing-complementary-immunomodulatory-effects-of-coya-303-in-neuroinflammation-model 2026-09-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-publishes-preclinical-data-showing-complementary-immunomodulatory-effects-of-coya-303-in-neuroinflammation-model 2026-09-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pepromene-bio-s-baff-r-car-t-cell-therapy-shows-80-complete-response-rate-in-relapsed-refractory-b-cell-lymphomas 2026-09-08T11:49:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pepromene-bio-s-baff-r-car-t-cell-therapy-shows-80-complete-response-rate-in-relapsed-refractory-b-cell-lymphomas 2026-09-08T11:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/egypt-s-eda-wins-who-prequalification-for-drug-quality-control-labs-cementing-maturity-level-3-status 2026-09-08T11:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egypt-s-eda-wins-who-prequalification-for-drug-quality-control-labs-cementing-maturity-level-3-status 2026-09-08T11:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/quality-over-quantity-specific-car-t-cell-subgroup-may-predict-low-dose-therapy-success 2026-09-08T11:49:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quality-over-quantity-specific-car-t-cell-subgroup-may-predict-low-dose-therapy-success 2026-09-08T11:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-shares-plunge-as-del-desiran-misses-primary-endpoint-in-myotonic-dystrophy-trial 2026-09-08T10:51:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-shares-plunge-as-del-desiran-misses-primary-endpoint-in-myotonic-dystrophy-trial 2026-09-08T10:51:01+00:00 hourly 0.9 https://trial.medpath.com/news/allergic-rhinoconjunctivitis-market-set-for-evolution-through-2036-as-immunotherapy-access-expands 2026-09-08T09:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allergic-rhinoconjunctivitis-market-set-for-evolution-through-2036-as-immunotherapy-access-expands 2026-09-08T09:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-nitinol-super-elastic-springs-reshape-baby-s-skull-in-craniosynostosis-surgery 2026-09-08T08:50:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-nitinol-super-elastic-springs-reshape-baby-s-skull-in-craniosynostosis-surgery 2026-09-08T08:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/multi-site-validation-study-confirms-diagnostic-grade-ai-biomarker-detection-from-routine-brightfield-images 2026-09-08T08:50:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-site-validation-study-confirms-diagnostic-grade-ai-biomarker-detection-from-routine-brightfield-images 2026-09-08T08:50:46+00:00 hourly 0.9 https://trial.medpath.com/news/panntherapi-receives-ansm-approval-to-advance-first-in-class-panx1-targeting-therapy-pti5803-into-phase-2a-in-focal-cortical-dysplasia 2026-09-08T08:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panntherapi-receives-ansm-approval-to-advance-first-in-class-panx1-targeting-therapy-pti5803-into-phase-2a-in-focal-cortical-dysplasia 2026-09-08T08:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/transgene-and-probiogen-expand-strategic-partnership-with-additional-license-for-age1-cr-pix-cell-line 2026-09-08T07:50:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transgene-and-probiogen-expand-strategic-partnership-with-additional-license-for-age1-cr-pix-cell-line 2026-09-08T07:50:52+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-map-the-enzymatic-route-that-builds-5-azacytidine-in-nature-revealing-a-rare-skeletal-editing-reaction 2026-09-08T07:50:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-map-the-enzymatic-route-that-builds-5-azacytidine-in-nature-revealing-a-rare-skeletal-editing-reaction 2026-09-08T07:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-advances-gs010-lumevoq-manufacturing-transfer-and-early-access-programs 2026-09-08T07:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensight-biologics-advances-gs010-lumevoq-manufacturing-transfer-and-early-access-programs 2026-09-08T07:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/deconstructing-lsd-s-ergoline-core-yields-simplified-compounds-with-reduced-hallucinogenic-and-cardiotoxic-effects 2026-09-08T04:49:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deconstructing-lsd-s-ergoline-core-yields-simplified-compounds-with-reduced-hallucinogenic-and-cardiotoxic-effects 2026-09-08T04:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-secures-10-year-brazil-supply-contract-for-pertuzumab-in-her2-positive-breast-cancer 2026-09-08T04:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-secures-10-year-brazil-supply-contract-for-pertuzumab-in-her2-positive-breast-cancer 2026-09-08T04:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/arm-holdings-ceo-ai-will-help-find-a-cure-for-cancer-within-our-lifetimes 2026-09-08T03:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arm-holdings-ceo-ai-will-help-find-a-cure-for-cancer-within-our-lifetimes 2026-09-08T03:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/tbe-base-editing-therapy-achieves-durable-remission-in-sickle-cell-disease-and-b-thalassemia-across-diverse-genetic-backgrounds 2026-09-08T01:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tbe-base-editing-therapy-achieves-durable-remission-in-sickle-cell-disease-and-b-thalassemia-across-diverse-genetic-backgrounds 2026-09-08T01:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/uk-pharma-investment-shows-green-shoots-with-ps2bn-committed-but-delivery-will-decide-recovery 2026-09-08T00:52:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-pharma-investment-shows-green-shoots-with-ps2bn-committed-but-delivery-will-decide-recovery 2026-09-08T00:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/convicted-murderer-erin-patterson-approved-for-taxpayer-funded-ozempic-in-victorian-prison 2026-09-08T00:52:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/convicted-murderer-erin-patterson-approved-for-taxpayer-funded-ozempic-in-victorian-prison 2026-09-08T00:52:04+00:00 hourly 0.9 https://trial.medpath.com/news/personalised-risk-adapted-therapy-doubles-six-year-survival-in-high-risk-multiple-myeloma 2026-09-08T00:50:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalised-risk-adapted-therapy-doubles-six-year-survival-in-high-risk-multiple-myeloma 2026-09-08T00:50:49+00:00 hourly 0.9 https://trial.medpath.com/news/prolight-signs-usd-3-9-million-supply-agreement-with-brainbox-for-tbi-point-of-care-diagnostics 2026-09-08T00:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prolight-signs-usd-3-9-million-supply-agreement-with-brainbox-for-tbi-point-of-care-diagnostics 2026-09-08T00:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/community-acquired-bacterial-pneumonia-market-poised-for-expansion-through-2036-amid-rising-antimicrobial-resistance 2026-09-07T19:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-acquired-bacterial-pneumonia-market-poised-for-expansion-through-2036-amid-rising-antimicrobial-resistance 2026-09-07T19:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/osf-cancer-institute-joins-hoosier-cancer-research-network-to-expand-trial-access-in-central-illinois 2026-09-07T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osf-cancer-institute-joins-hoosier-cancer-research-network-to-expand-trial-access-in-central-illinois 2026-09-07T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-cancer-drug-cadd522-shows-promise-against-osteoporosis-and-menopause-related-weight-gain 2026-09-07T17:50:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-cancer-drug-cadd522-shows-promise-against-osteoporosis-and-menopause-related-weight-gain 2026-09-07T17:50:58+00:00 hourly 0.9 https://trial.medpath.com/news/vascular-origins-of-alzheimer-s-disease-gain-ground-as-amyloid-hypothesis-faces-mounting-challenges 2026-09-07T17:49:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vascular-origins-of-alzheimer-s-disease-gain-ground-as-amyloid-hypothesis-faces-mounting-challenges 2026-09-07T17:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/erc-starting-grant-funds-in-vivo-car-t-cell-therapy-using-lipid-nanoparticles-and-genome-editing 2026-09-07T17:49:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/erc-starting-grant-funds-in-vivo-car-t-cell-therapy-using-lipid-nanoparticles-and-genome-editing 2026-09-07T17:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-supreme-court-rejects-pil-challenging-national-hpv-vaccination-programme 2026-09-07T17:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-supreme-court-rejects-pil-challenging-national-hpv-vaccination-programme 2026-09-07T17:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-and-aceso-therapeutics-partner-to-advance-inhaled-antisense-oligonucleotide-therapy-for-cystic-fibrosis 2026-09-07T16:49:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-and-aceso-therapeutics-partner-to-advance-inhaled-antisense-oligonucleotide-therapy-for-cystic-fibrosis 2026-09-07T16:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/new-initiative-seeks-500m-to-commercialize-israeli-life-science 2026-09-07T16:49:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-initiative-seeks-500m-to-commercialize-israeli-life-science 2026-09-07T16:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/drug-reconstitution-systems-market-poised-for-growth-through-2035-as-injectable-delivery-advances 2026-09-07T14:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-reconstitution-systems-market-poised-for-growth-through-2035-as-injectable-delivery-advances 2026-09-07T14:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/senate-to-hold-first-ever-congressional-hearing-on-menopause-as-women-s-health-research-funding-lags 2026-09-07T13:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-to-hold-first-ever-congressional-hearing-on-menopause-as-women-s-health-research-funding-lags 2026-09-07T13:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/king-s-college-hospital-recruits-world-s-first-patient-in-phase-3-trial-of-erlitercept-for-lower-risk-mds 2026-09-07T12:48:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/king-s-college-hospital-recruits-world-s-first-patient-in-phase-3-trial-of-erlitercept-for-lower-risk-mds 2026-09-07T12:48:57+00:00 hourly 0.9 https://trial.medpath.com/news/ibd-s-persistent-unmet-need-durable-remission-and-mucosal-healing-remain-the-missing-piece 2026-09-07T11:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibd-s-persistent-unmet-need-durable-remission-and-mucosal-healing-remain-the-missing-piece 2026-09-07T11:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/bi-multispecific-drugs-surge-in-oncology-278-new-candidates-added-in-2024-25 2026-09-07T10:50:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bi-multispecific-drugs-surge-in-oncology-278-new-candidates-added-in-2024-25 2026-09-07T10:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-india-to-acquire-pfizer-s-minipress-trademark-for-1250-crore 2026-09-07T10:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-india-to-acquire-pfizer-s-minipress-trademark-for-1250-crore 2026-09-07T10:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-nemolizumab-research-honored-with-11th-jbda-award-for-drug-discovery 2026-09-07T09:49:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-s-nemolizumab-research-honored-with-11th-jbda-award-for-drug-discovery 2026-09-07T09:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/liverpool-launches-uk-first-ps20m-high-security-robotic-ai-lab-to-accelerate-drug-and-vaccine-discovery 2026-09-07T09:49:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liverpool-launches-uk-first-ps20m-high-security-robotic-ai-lab-to-accelerate-drug-and-vaccine-discovery 2026-09-07T09:49:19+00:00 hourly 0.9 https://trial.medpath.com/news/sudarshan-pharma-to-acquire-9-5-stake-in-car-t-cell-cdmo-medtherapy-biotechnology 2026-09-07T08:49:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sudarshan-pharma-to-acquire-9-5-stake-in-car-t-cell-cdmo-medtherapy-biotechnology 2026-09-07T08:49:15+00:00 hourly 0.9 https://trial.medpath.com/news/bone-marrow-transplant-saves-alabama-boy-with-rare-wiskott-aldrich-syndrome 2026-09-07T08:49:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bone-marrow-transplant-saves-alabama-boy-with-rare-wiskott-aldrich-syndrome 2026-09-07T08:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/rznomics-reports-major-advances-in-high-efficiency-circular-rna-production 2026-09-07T08:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rznomics-reports-major-advances-in-high-efficiency-circular-rna-production 2026-09-07T08:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/louisiana-family-rallies-support-for-foxp1-syndrome-gene-therapy-research 2026-09-07T08:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/louisiana-family-rallies-support-for-foxp1-syndrome-gene-therapy-research 2026-09-07T08:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/nature-reviews-drug-discovery-review-positions-slc-transporters-as-untapped-frontier-in-cns-drug-development 2026-09-07T08:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-reviews-drug-discovery-review-positions-slc-transporters-as-untapped-frontier-in-cns-drug-development 2026-09-07T08:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/ondine-biomedical-partners-with-mexico-s-largest-private-hospital-network-to-pilot-steriwave-nasal-photodisinfection 2026-09-07T08:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ondine-biomedical-partners-with-mexico-s-largest-private-hospital-network-to-pilot-steriwave-nasal-photodisinfection 2026-09-07T08:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/laughter-therapy-eases-breathlessness-in-copd-patients-as-effectively-as-pursed-lip-breathing 2026-09-07T06:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laughter-therapy-eases-breathlessness-in-copd-patients-as-effectively-as-pursed-lip-breathing 2026-09-07T06:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/red-light-therapy-for-skin-aging-modest-evidence-real-risks-and-gaps-in-device-data 2026-09-07T06:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/red-light-therapy-for-skin-aging-modest-evidence-real-risks-and-gaps-in-device-data 2026-09-07T06:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/body-clock-may-speed-surgical-recovery-university-of-auckland-review-finds 2026-09-07T05:49:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/body-clock-may-speed-surgical-recovery-university-of-auckland-review-finds 2026-09-07T05:49:46+00:00 hourly 0.9 https://trial.medpath.com/news/decade-long-hiring-freeze-leaves-thousands-of-trained-medical-technicians-jobless-in-sindh 2026-09-07T05:49:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/decade-long-hiring-freeze-leaves-thousands-of-trained-medical-technicians-jobless-in-sindh 2026-09-07T05:49:10+00:00 hourly 0.9 https://trial.medpath.com/news/yonsei-cancer-hospital-expands-carbon-ion-therapy-to-stage-iv-oligometastatic-lung-cancer 2026-09-07T05:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yonsei-cancer-hospital-expands-carbon-ion-therapy-to-stage-iv-oligometastatic-lung-cancer 2026-09-07T05:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/india-releases-draft-2026-pharmaceutical-patent-examination-guidelines-rebuilding-examiner-toolkit-around-a-decade-of-case-law 2026-09-07T05:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-releases-draft-2026-pharmaceutical-patent-examination-guidelines-rebuilding-examiner-toolkit-around-a-decade-of-case-law 2026-09-07T05:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/peripheral-dendritic-cells-prime-cd8-t-cells-in-lymph-nodes-to-drive-tau-mediated-neurodegeneration 2026-09-07T04:49:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peripheral-dendritic-cells-prime-cd8-t-cells-in-lymph-nodes-to-drive-tau-mediated-neurodegeneration 2026-09-07T04:49:08+00:00 hourly 0.9 https://trial.medpath.com/news/waterford-family-fights-for-treatment-and-awareness-of-ultra-rare-cacna1e-genetic-disorder 2026-09-07T04:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waterford-family-fights-for-treatment-and-awareness-of-ultra-rare-cacna1e-genetic-disorder 2026-09-07T04:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/sechenov-university-advances-drug-repurposing-via-molecular-docking-for-three-new-indications 2026-09-07T04:49:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sechenov-university-advances-drug-repurposing-via-molecular-docking-for-three-new-indications 2026-09-07T04:49:04+00:00 hourly 0.9 https://trial.medpath.com/news/bubs-australia-secures-permanent-fda-approval-for-three-infant-formula-products-in-us-market 2026-09-07T03:48:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bubs-australia-secures-permanent-fda-approval-for-three-infant-formula-products-in-us-market 2026-09-07T03:48:42+00:00 hourly 0.9 https://trial.medpath.com/news/hanmi-pharmaceutical-to-fully-deploy-ai-across-quality-assurance-training-on-4000-sops 2026-09-07T03:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-to-fully-deploy-ai-across-quality-assurance-training-on-4000-sops 2026-09-07T03:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/hk-inno-n-s-kepacab-becomes-world-s-first-oral-finished-drug-to-earn-global-epd-certification 2026-09-07T03:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hk-inno-n-s-kepacab-becomes-world-s-first-oral-finished-drug-to-earn-global-epd-certification 2026-09-07T03:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/bbc-presenter-maryam-moshiri-reveals-two-year-battle-with-incurable-blood-cancer-polycythaemia-vera 2026-09-07T02:49:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bbc-presenter-maryam-moshiri-reveals-two-year-battle-with-incurable-blood-cancer-polycythaemia-vera 2026-09-07T02:49:20+00:00 hourly 0.9 https://trial.medpath.com/news/rezubio-announces-fda-and-nmpa-ind-clearances-and-first-cohort-dosing-of-rz-520-a-novel-inhaled-therapy-for-chronic-respiratory-diseases 2026-09-07T02:49:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezubio-announces-fda-and-nmpa-ind-clearances-and-first-cohort-dosing-of-rz-520-a-novel-inhaled-therapy-for-chronic-respiratory-diseases 2026-09-07T02:49:15+00:00 hourly 0.9 https://trial.medpath.com/news/wooree-group-calls-for-scientific-validation-standards-for-liposomal-claims-at-vitafoods-asia-2026 2026-09-07T02:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wooree-group-calls-for-scientific-validation-standards-for-liposomal-claims-at-vitafoods-asia-2026 2026-09-07T02:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/peppermint-oil-shows-promise-for-lowering-blood-pressure-in-20-day-clinical-trial 2026-09-07T00:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peppermint-oil-shows-promise-for-lowering-blood-pressure-in-20-day-clinical-trial 2026-09-07T00:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/il-10-s-dual-role-in-cancer-immunity-review-maps-context-dependent-framework-as-phase-iii-failure-tempers-enthusiasm 2026-09-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il-10-s-dual-role-in-cancer-immunity-review-maps-context-dependent-framework-as-phase-iii-failure-tempers-enthusiasm 2026-09-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clover-reports-positive-phase-2-data-for-rsv-hmpv-piv3-combination-vaccines-in-older-adults 2026-09-06T23:49:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clover-reports-positive-phase-2-data-for-rsv-hmpv-piv3-combination-vaccines-in-older-adults 2026-09-06T23:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/acrometa-to-enter-ambient-temperature-cellular-logistics-through-strategic-partnership-with-macro-hrd 2026-09-06T23:49:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acrometa-to-enter-ambient-temperature-cellular-logistics-through-strategic-partnership-with-macro-hrd 2026-09-06T23:49:02+00:00 hourly 0.9 https://trial.medpath.com/news/maternal-age-leaves-a-reversible-genotype-dependent-biological-mark-across-generations 2026-09-06T23:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maternal-age-leaves-a-reversible-genotype-dependent-biological-mark-across-generations 2026-09-06T23:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-heart-drug-pelacarsen-falls-short-in-trials-challenging-pipeline-strategy 2026-09-06T23:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-heart-drug-pelacarsen-falls-short-in-trials-challenging-pipeline-strategy 2026-09-06T23:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-director-sells-11600-shares-for-1-million 2026-09-06T23:48:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-director-sells-11600-shares-for-1-million 2026-09-06T23:48:30+00:00 hourly 0.9 https://trial.medpath.com/news/an-evening-for-cure-gala-advances-100m-comprehensive-cancer-center-for-ghana 2026-09-06T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an-evening-for-cure-gala-advances-100m-comprehensive-cancer-center-for-ghana 2026-09-06T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/cme-highlights-new-era-in-paediatric-oncology-and-bone-marrow-transplantation 2026-09-06T17:49:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cme-highlights-new-era-in-paediatric-oncology-and-bone-marrow-transplantation 2026-09-06T17:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/osuccc-james-appoints-d-neil-hayes-to-lead-precision-cancer-medicine-institute 2026-09-06T15:50:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osuccc-james-appoints-d-neil-hayes-to-lead-precision-cancer-medicine-institute 2026-09-06T15:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/eyepoint-s-duravyu-misses-primary-endpoint-in-phase-3-lugano-trial-for-wet-amd 2026-09-06T15:49:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyepoint-s-duravyu-misses-primary-endpoint-in-phase-3-lugano-trial-for-wet-amd 2026-09-06T15:49:59+00:00 hourly 0.9 https://trial.medpath.com/news/quaaludes-resurface-decades-after-us-ban-fueled-by-the-wolf-of-wall-street-and-underground-synthesis 2026-09-06T15:49:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quaaludes-resurface-decades-after-us-ban-fueled-by-the-wolf-of-wall-street-and-underground-synthesis 2026-09-06T15:49:55+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-kabi-and-aabb-launch-21st-annual-blood-collectors-week-september-6-12-2026 2026-09-06T15:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-kabi-and-aabb-launch-21st-annual-blood-collectors-week-september-6-12-2026 2026-09-06T15:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/sleep-apnea-strips-nocturnal-vagal-protection-in-type-1-diabetes-during-rem-sleep 2026-09-06T13:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sleep-apnea-strips-nocturnal-vagal-protection-in-type-1-diabetes-during-rem-sleep 2026-09-06T13:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/bioretec-receives-fda-510-k-clearance-for-activascrew-cannulated-com-bioabsorbable-compression-screw 2026-09-06T12:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioretec-receives-fda-510-k-clearance-for-activascrew-cannulated-com-bioabsorbable-compression-screw 2026-09-06T12:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/ebola-why-children-are-last-to-be-treated-in-medical-crises 2026-09-06T08:48:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ebola-why-children-are-last-to-be-treated-in-medical-crises 2026-09-06T08:48:58+00:00 hourly 0.9 https://trial.medpath.com/news/roivant-and-pulmovant-to-present-phase-2-phocus-data-for-mosliciguat-in-ph-ild-at-ers-2026 2026-09-06T07:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roivant-and-pulmovant-to-present-phase-2-phocus-data-for-mosliciguat-in-ph-ild-at-ers-2026 2026-09-06T07:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-maintains-hold-rating-as-competitor-c1s-faces-cidp-setback-while-claseprubart-advances 2026-09-06T05:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dianthus-maintains-hold-rating-as-competitor-c1s-faces-cidp-setback-while-claseprubart-advances 2026-09-06T05:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/cat-ownership-at-ages-4-5-linked-to-worse-mental-health-measures-in-children-at-ages-7-8 2026-09-06T02:48:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cat-ownership-at-ages-4-5-linked-to-worse-mental-health-measures-in-children-at-ages-7-8 2026-09-06T02:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/epivax-adds-ai-enabled-enhancements-to-ispri-immunogenicity-risk-platform 2026-09-06T00:48:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epivax-adds-ai-enabled-enhancements-to-ispri-immunogenicity-risk-platform 2026-09-06T00:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-approval-for-dipg-treatment-as-family-advocacy-fuels-research-momentum 2026-09-05T20:51:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-ever-approval-for-dipg-treatment-as-family-advocacy-fuels-research-momentum 2026-09-05T20:51:42+00:00 hourly 0.9 https://trial.medpath.com/news/patientiq-raises-30m-series-c-to-scale-ehr-integrated-outcomes-intelligence-platform 2026-09-05T20:51:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patientiq-raises-30m-series-c-to-scale-ehr-integrated-outcomes-intelligence-platform 2026-09-05T20:51:41+00:00 hourly 0.9 https://trial.medpath.com/news/14-people-hospitalized-during-the-chainsmokers-concert-in-san-jose 2026-09-05T20:51:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/14-people-hospitalized-during-the-chainsmokers-concert-in-san-jose 2026-09-05T20:51:40+00:00 hourly 0.9 https://trial.medpath.com/news/bruce-campbell-shares-five-year-prognosis-amid-battle-with-treatable-incurable-cancer 2026-09-05T20:49:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bruce-campbell-shares-five-year-prognosis-amid-battle-with-treatable-incurable-cancer 2026-09-05T20:49:10+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-drug-regulator-flags-counterfeit-abhayrab-rabies-vaccine-batch-after-failed-potency-test 2026-09-05T19:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-drug-regulator-flags-counterfeit-abhayrab-rabies-vaccine-batch-after-failed-potency-test 2026-09-05T19:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/nsf-awards-7-9-million-to-establish-vermont-s-pfas-environmental-research-network 2026-09-05T19:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsf-awards-7-9-million-to-establish-vermont-s-pfas-environmental-research-network 2026-09-05T19:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/branded-vs-compounded-glp-1s-a-cost-and-regulatory-comparison-of-wegovy-access-programs 2026-09-05T18:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/branded-vs-compounded-glp-1s-a-cost-and-regulatory-comparison-of-wegovy-access-programs 2026-09-05T18:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/lumbar-belts-may-ease-lower-back-pain-and-cut-medication-use-french-trial-finds 2026-09-05T18:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumbar-belts-may-ease-lower-back-pain-and-cut-medication-use-french-trial-finds 2026-09-05T18:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/illicit-anabolic-steroid-lab-uncovered-in-tennessee-home-three-arrested-on-drug-and-child-abuse-charges 2026-09-05T18:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illicit-anabolic-steroid-lab-uncovered-in-tennessee-home-three-arrested-on-drug-and-child-abuse-charges 2026-09-05T18:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/ovarian-cancer-survivors-highlight-biomarker-testing-and-equity-gaps-for-black-women 2026-09-05T17:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovarian-cancer-survivors-highlight-biomarker-testing-and-equity-gaps-for-black-women 2026-09-05T17:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/astrocyte-primary-cilia-emerge-as-a-new-stress-response-target-pointing-to-a-repurposed-ms-drug-for-anxiety-and-depression 2026-09-05T16:49:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrocyte-primary-cilia-emerge-as-a-new-stress-response-target-pointing-to-a-repurposed-ms-drug-for-anxiety-and-depression 2026-09-05T16:49:20+00:00 hourly 0.9 https://trial.medpath.com/news/cohance-lifescience-receives-usfda-form-483-with-four-observations-at-telangana-formulation-plant 2026-09-05T16:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cohance-lifescience-receives-usfda-form-483-with-four-observations-at-telangana-formulation-plant 2026-09-05T16:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/jubilant-biosys-strengthens-leadership-with-somesh-sharma-as-coo-of-drug-discovery-services 2026-09-05T16:48:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jubilant-biosys-strengthens-leadership-with-somesh-sharma-as-coo-of-drug-discovery-services 2026-09-05T16:48:42+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-charts-evidence-based-path-to-integrate-traditional-chinese-medicine-into-mainstream-healthcare 2026-09-05T16:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-charts-evidence-based-path-to-integrate-traditional-chinese-medicine-into-mainstream-healthcare 2026-09-05T16:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/chimpanzees-once-used-in-hepatitis-b-vaccine-research-receive-long-term-health-checks-in-liberia 2026-09-05T14:50:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chimpanzees-once-used-in-hepatitis-b-vaccine-research-receive-long-term-health-checks-in-liberia 2026-09-05T14:50:31+00:00 hourly 0.9 https://trial.medpath.com/news/nigerian-army-pursues-public-private-partnerships-to-modernise-military-healthcare-facilities 2026-09-05T14:49:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigerian-army-pursues-public-private-partnerships-to-modernise-military-healthcare-facilities 2026-09-05T14:49:39+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-therapies-vie-for-historic-first-inclusion-in-china-s-basic-medical-insurance-catalog 2026-09-05T13:48:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-therapies-vie-for-historic-first-inclusion-in-china-s-basic-medical-insurance-catalog 2026-09-05T13:48:58+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-bets-350-million-on-geroscience-to-extend-healthspan-nationwide 2026-09-05T12:48:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-bets-350-million-on-geroscience-to-extend-healthspan-nationwide 2026-09-05T12:48:34+00:00 hourly 0.9 https://trial.medpath.com/news/longview-passes-ordinance-criminalizing-child-exposure-to-schedule-i-and-ii-controlled-substances 2026-09-05T11:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longview-passes-ordinance-criminalizing-child-exposure-to-schedule-i-and-ii-controlled-substances 2026-09-05T11:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/army-doctor-testifies-she-is-investigating-whether-covid-19-vaccines-killed-u-s-troops 2026-09-05T10:48:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/army-doctor-testifies-she-is-investigating-whether-covid-19-vaccines-killed-u-s-troops 2026-09-05T10:48:48+00:00 hourly 0.9 https://trial.medpath.com/news/evinova-and-lothar-medical-partner-to-modernise-respiratory-clinical-trials-with-unified-digital-solution 2026-09-05T09:48:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evinova-and-lothar-medical-partner-to-modernise-respiratory-clinical-trials-with-unified-digital-solution 2026-09-05T09:48:42+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-review-finds-ceftriaxone-anaphylaxis-often-presents-without-rash-in-outpatient-settings 2026-09-05T07:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-review-finds-ceftriaxone-anaphylaxis-often-presents-without-rash-in-outpatient-settings 2026-09-05T07:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/cellular-quality-control-may-miss-nearly-half-of-certain-misfolded-proteins-raising-disease-risk 2026-09-05T06:48:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellular-quality-control-may-miss-nearly-half-of-certain-misfolded-proteins-raising-disease-risk 2026-09-05T06:48:30+00:00 hourly 0.9 https://trial.medpath.com/news/pemi-launches-women-s-daily-supplement-routine-built-specifically-for-perimenopause 2026-09-05T02:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pemi-launches-women-s-daily-supplement-routine-built-specifically-for-perimenopause 2026-09-05T02:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/voice-disorders-may-be-an-earlier-stronger-sign-of-dementia-than-hearing-loss-large-study-finds 2026-09-05T02:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voice-disorders-may-be-an-earlier-stronger-sign-of-dementia-than-hearing-loss-large-study-finds 2026-09-05T02:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-receives-first-settlement-under-sharing-agreement-with-sorbie-bornholm 2026-09-04T23:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/defence-therapeutics-receives-first-settlement-under-sharing-agreement-with-sorbie-bornholm 2026-09-04T23:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-withholds-pennsylvania-s-measles-deaths-from-national-dashboard-amid-political-standoff 2026-09-04T22:54:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-withholds-pennsylvania-s-measles-deaths-from-national-dashboard-amid-political-standoff 2026-09-04T22:54:31+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-pelacarsen-misses-primary-endpoint-in-lp-a-horizon-phase-iii-cardiovascular-outcomes-trial 2026-09-04T21:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-pelacarsen-misses-primary-endpoint-in-lp-a-horizon-phase-iii-cardiovascular-outcomes-trial 2026-09-04T21:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-neola-r-for-continuous-lung-monitoring-in-preterm-infants 2026-09-04T19:49:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-neola-r-for-continuous-lung-monitoring-in-preterm-infants 2026-09-04T19:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/alleged-lobbying-scandal-surrounds-covid-19-treatment-trial-approval-as-genencell-investment-value-evaporates 2026-09-04T18:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alleged-lobbying-scandal-surrounds-covid-19-treatment-trial-approval-as-genencell-investment-value-evaporates 2026-09-04T18:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/justice-minister-nominee-reported-to-police-over-alleged-lobbying-of-covid-19-drug-trial-approval 2026-09-04T18:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/justice-minister-nominee-reported-to-police-over-alleged-lobbying-of-covid-19-drug-trial-approval 2026-09-04T18:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/sheffield-honours-cecil-george-paine-pioneer-of-penicillin-s-therapeutic-use 2026-09-04T17:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sheffield-honours-cecil-george-paine-pioneer-of-penicillin-s-therapeutic-use 2026-09-04T17:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/brain-implant-trials-raise-unresolved-questions-about-post-trial-device-access 2026-09-04T17:48:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-implant-trials-raise-unresolved-questions-about-post-trial-device-access 2026-09-04T17:48:30+00:00 hourly 0.9 https://trial.medpath.com/news/hidalgo-county-deploys-five-free-naloxone-vending-machines-to-expand-overdose-antidote-access 2026-09-04T16:51:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hidalgo-county-deploys-five-free-naloxone-vending-machines-to-expand-overdose-antidote-access 2026-09-04T16:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/hair-based-testing-unlocks-a-molecular-movie-of-environmental-exposures 2026-09-04T16:49:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hair-based-testing-unlocks-a-molecular-movie-of-environmental-exposures 2026-09-04T16:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-sec-recommends-phase-3-trial-waiver-for-roche-s-subcutaneous-ocrelizumab-in-multiple-sclerosis 2026-09-04T16:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-sec-recommends-phase-3-trial-waiver-for-roche-s-subcutaneous-ocrelizumab-in-multiple-sclerosis 2026-09-04T16:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/nature-methods-publication-reveals-single-molecule-tau-proteoform-insights-for-alzheimer-s-disease 2026-09-04T14:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-methods-publication-reveals-single-molecule-tau-proteoform-insights-for-alzheimer-s-disease 2026-09-04T14:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-merck-s-ezmekly-mirdametinib-for-children-as-young-as-two-with-nf1-related-plexiform-neurofibromas 2026-09-04T14:49:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-recommends-merck-s-ezmekly-mirdametinib-for-children-as-young-as-two-with-nf1-related-plexiform-neurofibromas 2026-09-04T14:49:06+00:00 hourly 0.9 https://trial.medpath.com/news/autoimmune-diseases-form-distinct-genetic-clusters-rather-than-sharing-a-single-common-basis-swedish-registry-study-finds 2026-09-04T14:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autoimmune-diseases-form-distinct-genetic-clusters-rather-than-sharing-a-single-common-basis-swedish-registry-study-finds 2026-09-04T14:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/thryv-therapeutics-licenses-structurally-distinct-sgk1-inhibitors-to-expand-into-parkinson-s-and-alzheimer-s-disease 2026-09-04T13:48:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thryv-therapeutics-licenses-structurally-distinct-sgk1-inhibitors-to-expand-into-parkinson-s-and-alzheimer-s-disease 2026-09-04T13:48:58+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-patients-show-higher-microplastic-burden-in-lungs-study-finds 2026-09-04T13:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-cancer-patients-show-higher-microplastic-burden-in-lungs-study-finds 2026-09-04T13:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/tangram-s-tgm-312-advances-to-mash-patient-cohorts-in-phase-1-2-restore-mash-trial 2026-09-04T12:48:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tangram-s-tgm-312-advances-to-mash-patient-cohorts-in-phase-1-2-restore-mash-trial 2026-09-04T12:48:58+00:00 hourly 0.9 https://trial.medpath.com/news/acepodia-s-gpc3-targeted-dual-payload-adc-ace723-clears-fda-ind-for-hepatocellular-carcinoma 2026-09-04T12:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acepodia-s-gpc3-targeted-dual-payload-adc-ace723-clears-fda-ind-for-hepatocellular-carcinoma 2026-09-04T12:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/drug-resistant-fungus-trichophyton-indotineae-spreads-to-29-countries-cases-surge-sevenfold 2026-09-04T09:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-resistant-fungus-trichophyton-indotineae-spreads-to-29-countries-cases-surge-sevenfold 2026-09-04T09:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-warns-fresenius-over-leaking-sterile-dialysis-bags-and-cgmp-failures-at-ogden-plant 2026-09-04T09:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-warns-fresenius-over-leaking-sterile-dialysis-bags-and-cgmp-failures-at-ogden-plant 2026-09-04T09:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/menopause-is-missing-from-most-electronic-health-records-undermining-women-s-health-research 2026-09-04T07:50:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menopause-is-missing-from-most-electronic-health-records-undermining-women-s-health-research 2026-09-04T07:50:29+00:00 hourly 0.9 https://trial.medpath.com/news/unmc-marks-10-years-of-car-t-cell-therapy-innovation 2026-09-04T06:43:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unmc-marks-10-years-of-car-t-cell-therapy-innovation 2026-09-04T06:43:32+00:00 hourly 0.9 https://trial.medpath.com/news/alphagenome-atlas-maps-molecular-effects-of-all-9-billion-possible-human-dna-variants 2026-09-04T06:41:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphagenome-atlas-maps-molecular-effects-of-all-9-billion-possible-human-dna-variants 2026-09-04T06:41:49+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-drug-agency-recommends-conditional-reimbursement-for-yorvipath-in-chronic-hypoparathyroidism 2026-09-04T06:39:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-s-drug-agency-recommends-conditional-reimbursement-for-yorvipath-in-chronic-hypoparathyroidism 2026-09-04T06:39:53+00:00 hourly 0.9 https://trial.medpath.com/news/genetically-edited-pig-kidney-sustains-patient-for-record-271-days-serving-as-first-bridge-to-human-transplant 2026-09-04T06:39:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetically-edited-pig-kidney-sustains-patient-for-record-271-days-serving-as-first-bridge-to-human-transplant 2026-09-04T06:39:41+00:00 hourly 0.9 https://trial.medpath.com/news/patient-derived-organoid-screen-identifies-triple-drug-combination-against-liver-cancer 2026-09-04T06:39:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-derived-organoid-screen-identifies-triple-drug-combination-against-liver-cancer 2026-09-04T06:39:01+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-s-acccess-trial-meets-co-primary-endpoints-for-genio-in-complex-sleep-apnea-patients 2026-09-04T06:38:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyxoah-s-acccess-trial-meets-co-primary-endpoints-for-genio-in-complex-sleep-apnea-patients 2026-09-04T06:38:41+00:00 hourly 0.9 https://trial.medpath.com/news/eclincloud-surpasses-1100-clinical-trials-as-its-unified-ai-driven-platform-expands-across-10-countries 2026-09-04T06:38:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eclincloud-surpasses-1100-clinical-trials-as-its-unified-ai-driven-platform-expands-across-10-countries 2026-09-04T06:38:25+00:00 hourly 0.9 https://trial.medpath.com/news/2026-ig-nobel-prizes-honor-cockroach-milk-chemistry-and-a-cross-species-definition-of-kissing 2026-09-04T06:38:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2026-ig-nobel-prizes-honor-cockroach-milk-chemistry-and-a-cross-species-definition-of-kissing 2026-09-04T06:38:02+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-prevents-chemotherapy-induced-peripheral-neuropathy-in-preclinical-models-paving-the-way-for-a-phase-2-trial 2026-09-04T06:37:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilocybin-prevents-chemotherapy-induced-peripheral-neuropathy-in-preclinical-models-paving-the-way-for-a-phase-2-trial 2026-09-04T06:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/markel-launches-travel-reimbursement-scheme-to-boost-rare-disease-trial-enrollment 2026-09-04T06:37:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/markel-launches-travel-reimbursement-scheme-to-boost-rare-disease-trial-enrollment 2026-09-04T06:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/kkr-to-sell-minority-stake-in-nordic-bioscience-to-founder-claus-christiansen 2026-09-04T06:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kkr-to-sell-minority-stake-in-nordic-bioscience-to-founder-claus-christiansen 2026-09-04T06:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/persevere-therapeutics-appoints-james-barlow-to-board-as-myc-inhibitor-misetionamide-enters-phase-2 2026-09-04T06:30:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persevere-therapeutics-appoints-james-barlow-to-board-as-myc-inhibitor-misetionamide-enters-phase-2 2026-09-04T06:30:20+00:00 hourly 0.9 https://trial.medpath.com/news/celularity-and-musecell-innovations-strike-new-jersey-manufacturing-deal-worth-up-to-300-million 2026-09-04T06:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celularity-and-musecell-innovations-strike-new-jersey-manufacturing-deal-worth-up-to-300-million 2026-09-04T06:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/peptide-microdroplets-deliver-sirna-to-cut-colorectal-tumor-growth-by-67-in-mice 2026-09-04T06:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptide-microdroplets-deliver-sirna-to-cut-colorectal-tumor-growth-by-67-in-mice 2026-09-04T06:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/faa-proposes-easing-medical-certification-rules-for-pilots-with-non-insulin-dependent-diabetes 2026-09-04T06:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faa-proposes-easing-medical-certification-rules-for-pilots-with-non-insulin-dependent-diabetes 2026-09-04T06:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-seeks-public-input-to-advance-botanical-drug-product-development 2026-09-04T06:28:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-seeks-public-input-to-advance-botanical-drug-product-development 2026-09-04T06:28:31+00:00 hourly 0.9 https://trial.medpath.com/news/eight-year-multimuther-study-reveals-individual-molecular-aging-trajectories-diverge-from-population-patterns 2026-09-04T06:28:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eight-year-multimuther-study-reveals-individual-molecular-aging-trajectories-diverge-from-population-patterns 2026-09-04T06:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/regenicin-advances-autologous-cultured-skin-substitute-tiscela-toward-fda-clinical-trials-for-severe-burns 2026-09-04T06:25:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenicin-advances-autologous-cultured-skin-substitute-tiscela-toward-fda-clinical-trials-for-severe-burns 2026-09-04T06:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/resonant-clinical-solutions-acquires-creapharm-bioservices-to-expand-cryogenic-storage-and-advanced-therapy-capabilities 2026-09-04T06:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resonant-clinical-solutions-acquires-creapharm-bioservices-to-expand-cryogenic-storage-and-advanced-therapy-capabilities 2026-09-04T06:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/family-offices-quietly-power-biotech-s-funding-comeback-backing-gene-therapy-and-ai-driven-drug-discovery 2026-09-04T06:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/family-offices-quietly-power-biotech-s-funding-comeback-backing-gene-therapy-and-ai-driven-drug-discovery 2026-09-04T06:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/cellipont-bioservices-texas-facility-advances-six-cell-therapy-programs-toward-ind-submission-in-2026 2026-09-04T06:23:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellipont-bioservices-texas-facility-advances-six-cell-therapy-programs-toward-ind-submission-in-2026 2026-09-04T06:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/nexalin-s-item-level-adas-cog-analysis-reveals-domain-specific-cognitive-gains-in-alzheimer-s-trial 2026-09-04T06:22:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexalin-s-item-level-adas-cog-analysis-reveals-domain-specific-cognitive-gains-in-alzheimer-s-trial 2026-09-04T06:22:39+00:00 hourly 0.9 https://trial.medpath.com/news/northway-biotech-opens-first-baltic-cell-therapy-and-personalized-medicine-cdmo-in-vilnius 2026-09-04T06:21:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northway-biotech-opens-first-baltic-cell-therapy-and-personalized-medicine-cdmo-in-vilnius 2026-09-04T06:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/biological-age-and-longevity-diagnostics-market-projected-to-reach-5-58-billion-by-2030 2026-09-04T06:21:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biological-age-and-longevity-diagnostics-market-projected-to-reach-5-58-billion-by-2030 2026-09-04T06:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/i-m-greentm-bio-based-polymer-helps-deterra-r-drug-disposal-pouch-win-multiple-packaging-industry-awards 2026-09-04T06:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/i-m-greentm-bio-based-polymer-helps-deterra-r-drug-disposal-pouch-win-multiple-packaging-industry-awards 2026-09-04T06:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/frost-sullivan-2026-blue-book-charts-hong-kong-18a-biotech-sector-s-shift-toward-value-driven-growth 2026-09-04T06:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frost-sullivan-2026-blue-book-charts-hong-kong-18a-biotech-sector-s-shift-toward-value-driven-growth 2026-09-04T06:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-oxford-and-2u-launch-ai-in-drug-discovery-and-medicine-programme 2026-09-04T06:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-oxford-and-2u-launch-ai-in-drug-discovery-and-medicine-programme 2026-09-04T06:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/lumirix-r-ruxolitinib-phosphate-cream-approved-in-china-for-mild-to-moderate-atopic-dermatitis 2026-09-04T06:19:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumirix-r-ruxolitinib-phosphate-cream-approved-in-china-for-mild-to-moderate-atopic-dermatitis 2026-09-04T06:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/armata-publishes-near-atomic-structural-atlas-of-pseudomonas-phage-ar-km-illuminating-genome-ejection-mechanism 2026-09-04T06:18:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/armata-publishes-near-atomic-structural-atlas-of-pseudomonas-phage-ar-km-illuminating-genome-ejection-mechanism 2026-09-04T06:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-secures-global-license-from-pfizer-for-cd228-targeting-adc-valued-at-over-1-billion-in-milestones 2026-09-04T06:16:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-secures-global-license-from-pfizer-for-cd228-targeting-adc-valued-at-over-1-billion-in-milestones 2026-09-04T06:16:23+00:00 hourly 0.9 https://trial.medpath.com/news/targeting-kv7-4-channels-could-delay-preterm-birth-preclinical-study-finds 2026-09-04T06:15:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeting-kv7-4-channels-could-delay-preterm-birth-preclinical-study-finds 2026-09-04T06:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-experts-call-for-regulatory-reforms-to-advance-precision-medicine-and-patient-care-in-south-korea 2026-09-04T06:15:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthcare-experts-call-for-regulatory-reforms-to-advance-precision-medicine-and-patient-care-in-south-korea 2026-09-04T06:15:32+00:00 hourly 0.9 https://trial.medpath.com/news/fangzhou-s-ai-powered-chronic-care-model-named-to-fortune-china-s-best-designs-2026 2026-09-04T06:15:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fangzhou-s-ai-powered-chronic-care-model-named-to-fortune-china-s-best-designs-2026 2026-09-04T06:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/personalised-medicine-shows-early-success-in-preventing-kidney-injury-after-major-surgery 2026-09-04T06:14:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalised-medicine-shows-early-success-in-preventing-kidney-injury-after-major-surgery 2026-09-04T06:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/superluminal-medicines-raises-60m-series-b-to-advance-mc4r-agonist-for-rare-genetic-obesity-into-the-clinic 2026-09-04T06:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/superluminal-medicines-raises-60m-series-b-to-advance-mc4r-agonist-for-rare-genetic-obesity-into-the-clinic 2026-09-04T06:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/idbs-advances-drug-development-with-polar-platform-innovations-and-ai-investments-in-2025 2026-09-04T06:10:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idbs-advances-drug-development-with-polar-platform-innovations-and-ai-investments-in-2025 2026-09-04T06:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-science-based-crackdown-on-unproven-stem-cell-clinics-marks-a-surprising-regulatory-bright-spot 2026-09-04T06:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-science-based-crackdown-on-unproven-stem-cell-clinics-marks-a-surprising-regulatory-bright-spot 2026-09-04T06:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/cytosorb-cuts-severe-bleeding-by-37-in-urgent-cabg-patients-on-ticagrelor-real-world-data-show 2026-09-04T06:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytosorb-cuts-severe-bleeding-by-37-in-urgent-cabg-patients-on-ticagrelor-real-world-data-show 2026-09-04T06:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-s-mounjaro-sales-hit-r1-5-billion-as-it-readies-generic-semaglutide-push-across-africa 2026-09-04T06:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspen-s-mounjaro-sales-hit-r1-5-billion-as-it-readies-generic-semaglutide-push-across-africa 2026-09-04T06:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-protein-vehicles-outperform-lipid-nanoparticles-for-rna-and-crispr-delivery 2026-09-04T06:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-protein-vehicles-outperform-lipid-nanoparticles-for-rna-and-crispr-delivery 2026-09-04T06:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/asia-bio-partnering-forum-2026-data-ai-and-platform-intelligence-reshape-how-apac-biotechs-are-valued 2026-09-04T06:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asia-bio-partnering-forum-2026-data-ai-and-platform-intelligence-reshape-how-apac-biotechs-are-valued 2026-09-04T06:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/systemic-antifungal-fluconazole-may-ease-ibd-disease-activity-by-restoring-gut-microbiome 2026-09-04T06:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systemic-antifungal-fluconazole-may-ease-ibd-disease-activity-by-restoring-gut-microbiome 2026-09-04T06:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/encoded-therapeutics-etx101-gene-therapy-shows-durable-seizure-reduction-and-neurodevelopmental-gains-in-dravet-syndrome 2026-09-04T06:03:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/encoded-therapeutics-etx101-gene-therapy-shows-durable-seizure-reduction-and-neurodevelopmental-gains-in-dravet-syndrome 2026-09-04T06:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/community-pharmacists-perceived-barriers-and-drivers-toward-vaccination-services-in-saudi-arabia 2026-09-04T06:02:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-pharmacists-perceived-barriers-and-drivers-toward-vaccination-services-in-saudi-arabia 2026-09-04T06:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/sec-and-fda-sign-memorandum-of-understanding-to-share-information-on-fda-regulated-products 2026-09-04T05:59:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sec-and-fda-sign-memorandum-of-understanding-to-share-information-on-fda-regulated-products 2026-09-04T05:59:31+00:00 hourly 0.9 https://trial.medpath.com/news/ncrha-reforms-patient-escort-and-hospital-attendant-services-after-review-uncovers-alleged-gang-activity-and-widespread-misconduct 2026-09-04T05:59:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ncrha-reforms-patient-escort-and-hospital-attendant-services-after-review-uncovers-alleged-gang-activity-and-widespread-misconduct 2026-09-04T05:59:16+00:00 hourly 0.9 https://trial.medpath.com/news/huge-gwas-links-over-1200-genetic-variants-to-the-big-five-personality-traits 2026-09-04T05:58:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huge-gwas-links-over-1200-genetic-variants-to-the-big-five-personality-traits 2026-09-04T05:58:39+00:00 hourly 0.9 https://trial.medpath.com/news/global-mpox-vaccine-stockpile-launched-to-strengthen-equitable-outbreak-response 2026-09-04T05:56:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-mpox-vaccine-stockpile-launched-to-strengthen-equitable-outbreak-response 2026-09-04T05:56:25+00:00 hourly 0.9 https://trial.medpath.com/news/barda-exercises-36-9-million-option-to-stockpile-cefiderocol-a-last-resort-antibiotic-for-drug-resistant-gram-negative-infections 2026-09-04T05:55:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/barda-exercises-36-9-million-option-to-stockpile-cefiderocol-a-last-resort-antibiotic-for-drug-resistant-gram-negative-infections 2026-09-04T05:55:05+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-opens-two-new-research-buildings-in-largest-research-investment-in-its-history 2026-09-04T05:54:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-opens-two-new-research-buildings-in-largest-research-investment-in-its-history 2026-09-04T05:54:34+00:00 hourly 0.9 https://trial.medpath.com/news/multicellular-3d-tumor-spheroids-emerge-as-a-predictive-bridge-between-2d-assays-and-solid-tumors-in-preclinical-drug-testing 2026-09-02T21:50:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multicellular-3d-tumor-spheroids-emerge-as-a-predictive-bridge-between-2d-assays-and-solid-tumors-in-preclinical-drug-testing 2026-09-02T21:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/two-scientists-win-2026-horwitz-prize-for-rett-syndrome-breakthrough 2026-09-02T21:49:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-scientists-win-2026-horwitz-prize-for-rett-syndrome-breakthrough 2026-09-02T21:49:15+00:00 hourly 0.9 https://trial.medpath.com/news/mito-health-passes-one-million-lab-tests-expands-into-seven-preventive-testing-categories 2026-09-02T21:48:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mito-health-passes-one-million-lab-tests-expands-into-seven-preventive-testing-categories 2026-09-02T21:48:33+00:00 hourly 0.9 https://trial.medpath.com/news/450-nurses-to-strike-at-west-anaheim-medical-center-over-patient-care-and-staffing-concerns 2026-09-02T21:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/450-nurses-to-strike-at-west-anaheim-medical-center-over-patient-care-and-staffing-concerns 2026-09-02T21:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-launches-overdose-prevention-data-channel-amid-12-3-decline-in-drug-overdose-deaths 2026-09-02T20:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-launches-overdose-prevention-data-channel-amid-12-3-decline-in-drug-overdose-deaths 2026-09-02T20:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/labradoodle-s-persistent-sniffing-leads-to-early-melanoma-diagnosis-in-chicago-heights-woman 2026-09-02T19:50:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labradoodle-s-persistent-sniffing-leads-to-early-melanoma-diagnosis-in-chicago-heights-woman 2026-09-02T19:50:41+00:00 hourly 0.9 https://trial.medpath.com/news/smt-launches-safe-pfo-trial-first-head-to-head-comparison-of-cocoon-and-amplatzer-pfo-closure-devices 2026-09-02T19:49:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smt-launches-safe-pfo-trial-first-head-to-head-comparison-of-cocoon-and-amplatzer-pfo-closure-devices 2026-09-02T19:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-ub-hwi-s-national-crystallization-center-5-5-million-to-advance-structural-biology 2026-09-02T19:49:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-ub-hwi-s-national-crystallization-center-5-5-million-to-advance-structural-biology 2026-09-02T19:49:47+00:00 hourly 0.9 https://trial.medpath.com/news/altria-sues-fda-to-overhaul-tobacco-product-review-system 2026-09-02T19:49:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altria-sues-fda-to-overhaul-tobacco-product-review-system 2026-09-02T19:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-mprosevir-the-world-s-first-ai-and-del-discovered-covid-19-drug 2026-09-02T18:49:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-mprosevir-the-world-s-first-ai-and-del-discovered-covid-19-drug 2026-09-02T18:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/waterfall-scientific-awarded-up-to-54-5-million-from-arpa-h-to-lead-continuous-flow-mrna-manufacturing-consortium 2026-09-02T18:48:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waterfall-scientific-awarded-up-to-54-5-million-from-arpa-h-to-lead-continuous-flow-mrna-manufacturing-consortium 2026-09-02T18:48:30+00:00 hourly 0.9 https://trial.medpath.com/news/adjunctive-lumateperone-improves-sexual-function-in-mdd-patients-with-inadequate-antidepressant-response 2026-09-02T17:50:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjunctive-lumateperone-improves-sexual-function-in-mdd-patients-with-inadequate-antidepressant-response 2026-09-02T17:50:57+00:00 hourly 0.9 https://trial.medpath.com/news/cencora-launches-cell-and-gene-therapy-enablement-to-help-health-systems-build-and-scale-cgt-programs 2026-09-02T17:49:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cencora-launches-cell-and-gene-therapy-enablement-to-help-health-systems-build-and-scale-cgt-programs 2026-09-02T17:49:35+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-dedicated-smoking-cessation-guidelines-for-type-2-diabetes-released-by-global-experts 2026-09-02T17:49:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-dedicated-smoking-cessation-guidelines-for-type-2-diabetes-released-by-global-experts 2026-09-02T17:49:02+00:00 hourly 0.9 https://trial.medpath.com/news/formosa-pharmaceuticals-targets-first-adc-biosimilar-launch-in-us-and-europe-with-tsy-110 2026-09-02T16:51:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formosa-pharmaceuticals-targets-first-adc-biosimilar-launch-in-us-and-europe-with-tsy-110 2026-09-02T16:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/onymos-and-vanta-diagnostics-report-ai-assisted-lab-intake-boosts-efficiency-by-72-and-cuts-errors-by-40 2026-09-02T16:50:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onymos-and-vanta-diagnostics-report-ai-assisted-lab-intake-boosts-efficiency-by-72-and-cuts-errors-by-40 2026-09-02T16:50:56+00:00 hourly 0.9 https://trial.medpath.com/news/iss-national-lab-reaches-1000-payload-milestone-as-casis-marks-15-years-of-space-based-r-d-leadership 2026-09-02T16:50:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iss-national-lab-reaches-1000-payload-milestone-as-casis-marks-15-years-of-space-based-r-d-leadership 2026-09-02T16:50:55+00:00 hourly 0.9 https://trial.medpath.com/news/multi-modality-analytical-strategies-aim-to-overcome-bottlenecks-in-next-gen-cell-and-gene-therapy-development 2026-09-02T16:50:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-modality-analytical-strategies-aim-to-overcome-bottlenecks-in-next-gen-cell-and-gene-therapy-development 2026-09-02T16:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/treeline-and-roche-collaborate-on-phase-1-trial-of-bcl6-degrader-tln-121-combined-with-cd20xcd3-bispecifics-in-b-cell-lymphomas 2026-09-02T16:50:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treeline-and-roche-collaborate-on-phase-1-trial-of-bcl6-degrader-tln-121-combined-with-cd20xcd3-bispecifics-in-b-cell-lymphomas 2026-09-02T16:50:26+00:00 hourly 0.9 https://trial.medpath.com/news/lifecore-biomedical-signs-commercial-transfer-agreement-for-marketed-injectable-product 2026-09-02T16:50:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifecore-biomedical-signs-commercial-transfer-agreement-for-marketed-injectable-product 2026-09-02T16:50:23+00:00 hourly 0.9 https://trial.medpath.com/news/switzerland-to-boost-funding-and-establish-a-national-register-for-rare-diseases 2026-09-02T16:50:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/switzerland-to-boost-funding-and-establish-a-national-register-for-rare-diseases 2026-09-02T16:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/ubs-lifts-j-j-price-target-to-320-on-oncology-and-immunology-growth-outlook 2026-09-02T16:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ubs-lifts-j-j-price-target-to-320-on-oncology-and-immunology-growth-outlook 2026-09-02T16:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-associated-macrophages-emerge-as-central-drivers-of-gastric-cancer-peritoneal-metastasis-and-immunotherapy-resistance 2026-09-02T15:51:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-associated-macrophages-emerge-as-central-drivers-of-gastric-cancer-peritoneal-metastasis-and-immunotherapy-resistance 2026-09-02T15:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-to-present-seven-precision-oncology-studies-at-iaslc-2026-world-conference-on-lung-cancer 2026-09-02T15:50:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-to-present-seven-precision-oncology-studies-at-iaslc-2026-world-conference-on-lung-cancer 2026-09-02T15:50:03+00:00 hourly 0.9 https://trial.medpath.com/news/purple-biotech-secures-u-s-patent-allowance-for-captn-3-tri-specific-antibody-platform 2026-09-02T15:50:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purple-biotech-secures-u-s-patent-allowance-for-captn-3-tri-specific-antibody-platform 2026-09-02T15:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/bioaffinity-technologies-advances-cypath-lung-into-post-treatment-lung-cancer-surveillance 2026-09-02T15:49:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioaffinity-technologies-advances-cypath-lung-into-post-treatment-lung-cancer-surveillance 2026-09-02T15:49:49+00:00 hourly 0.9 https://trial.medpath.com/news/fortrea-to-acquire-early-phase-services-from-worldwide-clinical-trials-in-45m-deal 2026-09-02T15:49:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fortrea-to-acquire-early-phase-services-from-worldwide-clinical-trials-in-45m-deal 2026-09-02T15:49:45+00:00 hourly 0.9 https://trial.medpath.com/news/bayesian-health-s-fda-cleared-ai-sepsis-monitor-wins-first-medicare-ntap-reimbursement-pathway 2026-09-02T15:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayesian-health-s-fda-cleared-ai-sepsis-monitor-wins-first-medicare-ntap-reimbursement-pathway 2026-09-02T15:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/rna-polymerase-accurately-transcribes-an-eight-letter-genetic-alphabet-expanding-synthetic-biology 2026-09-02T15:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rna-polymerase-accurately-transcribes-an-eight-letter-genetic-alphabet-expanding-synthetic-biology 2026-09-02T15:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/qualcomm-and-asus-launch-on-premises-pharmaceutical-ai-agent-for-community-pharmacies-in-southern-taiwan 2026-09-02T14:48:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qualcomm-and-asus-launch-on-premises-pharmaceutical-ai-agent-for-community-pharmacies-in-southern-taiwan 2026-09-02T14:48:58+00:00 hourly 0.9 https://trial.medpath.com/news/cmc-bottleneck-is-choking-biopharma-s-drug-pipeline-says-zifo 2026-09-02T14:48:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cmc-bottleneck-is-choking-biopharma-s-drug-pipeline-says-zifo 2026-09-02T14:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/benchsci-and-argenx-sign-two-year-enterprise-agreement-to-deploy-ai-driven-preclinical-drug-discovery-platform 2026-09-02T14:48:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benchsci-and-argenx-sign-two-year-enterprise-agreement-to-deploy-ai-driven-preclinical-drug-discovery-platform 2026-09-02T14:48:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-gene-therapy-clinical-trial-for-ultra-rare-pediatric-neurodegenerative-disease-mliv 2026-09-02T13:51:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-gene-therapy-clinical-trial-for-ultra-rare-pediatric-neurodegenerative-disease-mliv 2026-09-02T13:51:26+00:00 hourly 0.9 https://trial.medpath.com/news/mizzou-researchers-uncover-promising-new-target-for-treating-high-blood-pressure 2026-09-02T13:49:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mizzou-researchers-uncover-promising-new-target-for-treating-high-blood-pressure 2026-09-02T13:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-adds-boxed-warning-to-injectafer-for-risk-of-symptomatic-hypophosphatemia 2026-09-02T13:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-adds-boxed-warning-to-injectafer-for-risk-of-symptomatic-hypophosphatemia 2026-09-02T13:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/raziel-and-fosun-report-positive-phase-3-results-for-rzl-012-in-submental-fat-reduction-paving-path-to-china-nda 2026-09-02T13:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raziel-and-fosun-report-positive-phase-3-results-for-rzl-012-in-submental-fat-reduction-paving-path-to-china-nda 2026-09-02T13:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-and-plectonic-partner-to-develop-logic-gated-t-cell-engagers-for-solid-tumors 2026-09-02T12:48:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-and-plectonic-partner-to-develop-logic-gated-t-cell-engagers-for-solid-tumors 2026-09-02T12:48:42+00:00 hourly 0.9 https://trial.medpath.com/news/repatha-sales-surge-37-to-953-million-as-amgen-s-overlooked-cardiovascular-growth-driver-gains-momentum 2026-09-02T11:48:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repatha-sales-surge-37-to-953-million-as-amgen-s-overlooked-cardiovascular-growth-driver-gains-momentum 2026-09-02T11:48:43+00:00 hourly 0.9 https://trial.medpath.com/news/braveheart-bio-to-present-at-cantor-global-healthcare-conference-as-it-advances-bhb-1893-for-hypertrophic-cardiomyopathy 2026-09-02T11:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/braveheart-bio-to-present-at-cantor-global-healthcare-conference-as-it-advances-bhb-1893-for-hypertrophic-cardiomyopathy 2026-09-02T11:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/neuropace-to-present-rns-system-at-cantor-and-wells-fargo-healthcare-conferences 2026-09-02T11:48:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuropace-to-present-rns-system-at-cantor-and-wells-fargo-healthcare-conferences 2026-09-02T11:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/medipost-recruits-samsung-biologics-veteran-min-ho-sung-to-lead-cartistem-s-global-expansion 2026-09-02T10:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medipost-recruits-samsung-biologics-veteran-min-ho-sung-to-lead-cartistem-s-global-expansion 2026-09-02T10:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/blood-cancer-united-launches-2026-light-the-night-season-to-advance-blood-cancer-research-and-support 2026-09-02T10:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-cancer-united-launches-2026-light-the-night-season-to-advance-blood-cancer-research-and-support 2026-09-02T10:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/bc-platforms-launches-bc-mosaic-app-store-to-empower-data-scientists-and-healthcare-researchers 2026-09-02T09:49:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bc-platforms-launches-bc-mosaic-app-store-to-empower-data-scientists-and-healthcare-researchers 2026-09-02T09:49:18+00:00 hourly 0.9 https://trial.medpath.com/news/newbiologix-and-synastra-partner-to-advance-stable-raav-manufacturing-for-duchenne-muscular-dystrophy-gene-therapy 2026-09-02T09:49:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newbiologix-and-synastra-partner-to-advance-stable-raav-manufacturing-for-duchenne-muscular-dystrophy-gene-therapy 2026-09-02T09:49:06+00:00 hourly 0.9 https://trial.medpath.com/news/unist-blood-filtering-technology-aims-to-block-cancer-metastasis-before-it-begins 2026-09-02T09:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unist-blood-filtering-technology-aims-to-block-cancer-metastasis-before-it-begins 2026-09-02T09:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/desiccant-closures-market-to-reach-usd-937-2-million-by-2036-as-integrated-moisture-control-reshapes-pharmaceutical-packaging 2026-09-02T06:48:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/desiccant-closures-market-to-reach-usd-937-2-million-by-2036-as-integrated-moisture-control-reshapes-pharmaceutical-packaging 2026-09-02T06:48:30+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-granted-fda-fast-track-designation-for-bv100-in-carbapenem-resistant-acinetobacter-pneumonia 2026-09-02T05:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioversys-granted-fda-fast-track-designation-for-bv100-in-carbapenem-resistant-acinetobacter-pneumonia 2026-09-02T05:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/weight-loss-supplement-recalled-after-fda-finds-undeclared-fluoxetine-and-toxic-dnp 2026-09-02T05:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-loss-supplement-recalled-after-fda-finds-undeclared-fluoxetine-and-toxic-dnp 2026-09-02T05:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/idt-and-ansa-biotechnologies-expand-partnership-to-streamline-access-to-complex-dna-constructs 2026-09-02T03:57:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idt-and-ansa-biotechnologies-expand-partnership-to-streamline-access-to-complex-dna-constructs 2026-09-02T03:57:50+00:00 hourly 0.9 https://trial.medpath.com/news/vitrafy-life-sciences-enters-us-cell-and-gene-therapy-market-with-cryopreservation-agreement 2026-09-02T03:56:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitrafy-life-sciences-enters-us-cell-and-gene-therapy-market-with-cryopreservation-agreement 2026-09-02T03:56:51+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharma-partners-with-aitia-to-use-causal-ai-digital-twins-for-neurological-drug-discovery 2026-09-02T02:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-pharma-partners-with-aitia-to-use-causal-ai-digital-twins-for-neurological-drug-discovery 2026-09-02T02:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/rutgers-led-team-identifies-36-genes-tied-to-ocd-and-tic-disorders-opening-new-treatment-targets 2026-09-02T00:50:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rutgers-led-team-identifies-36-genes-tied-to-ocd-and-tic-disorders-opening-new-treatment-targets 2026-09-02T00:50:58+00:00 hourly 0.9 https://trial.medpath.com/news/idsa-and-hivma-warn-proposed-niaid-restructuring-threatens-u-s-infectious-disease-research-and-hiv-response 2026-09-01T23:52:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idsa-and-hivma-warn-proposed-niaid-restructuring-threatens-u-s-infectious-disease-research-and-hiv-response 2026-09-01T23:52:51+00:00 hourly 0.9 https://trial.medpath.com/news/study-identifies-risk-groups-for-ketoacidosis-a-severe-side-effect-of-sglt2-inhibitors 2026-09-01T23:52:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-identifies-risk-groups-for-ketoacidosis-a-severe-side-effect-of-sglt2-inhibitors 2026-09-01T23:52:51+00:00 hourly 0.9 https://trial.medpath.com/news/collplant-acquires-lightsolver-to-enter-photonic-computing-market 2026-09-01T23:52:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/collplant-acquires-lightsolver-to-enter-photonic-computing-market 2026-09-01T23:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/scopia-surgical-raises-c-2-65-million-to-build-ai-gps-for-robotic-surgery 2026-09-01T23:51:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scopia-surgical-raises-c-2-65-million-to-build-ai-gps-for-robotic-surgery 2026-09-01T23:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/leukemia-research-foundation-funds-uc-study-targeting-rhoa-in-tp53-mutated-aml 2026-09-01T22:55:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leukemia-research-foundation-funds-uc-study-targeting-rhoa-in-tp53-mutated-aml 2026-09-01T22:55:44+00:00 hourly 0.9 https://trial.medpath.com/news/systech-launches-traceiq-an-ai-powered-traceability-platform-for-pharmaceutical-supply-chains 2026-09-01T22:54:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systech-launches-traceiq-an-ai-powered-traceability-platform-for-pharmaceutical-supply-chains 2026-09-01T22:54:07+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-health-launches-pediatric-cardiology-and-hospital-medicine-fellowships-to-address-subspecialist-shortages 2026-09-01T21:54:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-health-launches-pediatric-cardiology-and-hospital-medicine-fellowships-to-address-subspecialist-shortages 2026-09-01T21:54:20+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-wins-fda-de-novo-authorization-for-first-surgical-app-on-apple-vision-pro-completes-first-hip-arthroscopy 2026-09-01T20:54:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stryker-wins-fda-de-novo-authorization-for-first-surgical-app-on-apple-vision-pro-completes-first-hip-arthroscopy 2026-09-01T20:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-reshuffles-r-d-leadership-as-andrea-haegebarth-joins-to-lead-global-research 2026-09-01T20:52:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-reshuffles-r-d-leadership-as-andrea-haegebarth-joins-to-lead-global-research 2026-09-01T20:52:38+00:00 hourly 0.9 https://trial.medpath.com/news/skinmedica-launches-barrier-calming-cream-to-support-regenerative-skincare-and-skin-barrier-health 2026-09-01T18:49:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skinmedica-launches-barrier-calming-cream-to-support-regenerative-skincare-and-skin-barrier-health 2026-09-01T18:49:49+00:00 hourly 0.9 https://trial.medpath.com/news/blood-cancer-treatment-advances-have-saved-nearly-26-million-years-of-life-over-75-years 2026-09-01T18:49:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-cancer-treatment-advances-have-saved-nearly-26-million-years-of-life-over-75-years 2026-09-01T18:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/medincell-appoints-edna-venneker-md-as-chief-medical-officer 2026-09-01T18:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medincell-appoints-edna-venneker-md-as-chief-medical-officer 2026-09-01T18:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/simcere-zaiming-licenses-tri-specific-antibody-sim0660-to-roche-in-deal-worth-up-to-1-53-billion 2026-09-01T18:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simcere-zaiming-licenses-tri-specific-antibody-sim0660-to-roche-in-deal-worth-up-to-1-53-billion 2026-09-01T18:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/n-power-medicine-closes-32-million-series-b-to-expand-community-oncology-network-and-proeca-platform 2026-09-01T18:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/n-power-medicine-closes-32-million-series-b-to-expand-community-oncology-network-and-proeca-platform 2026-09-01T18:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/bighat-s-ai-designed-cdh17-antibody-drug-conjugate-bhb810-enters-first-in-human-trial-for-gastric-cancer 2026-09-01T17:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bighat-s-ai-designed-cdh17-antibody-drug-conjugate-bhb810-enters-first-in-human-trial-for-gastric-cancer 2026-09-01T17:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/chfa-names-eight-emerging-canadian-wellness-brands-as-finalists-for-2026-launch-pad-competition 2026-09-01T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chfa-names-eight-emerging-canadian-wellness-brands-as-finalists-for-2026-launch-pad-competition 2026-09-01T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/mizzou-researchers-pursue-first-drug-treatment-for-aortic-valve-calcification-targeting-dock2 2026-09-01T16:51:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mizzou-researchers-pursue-first-drug-treatment-for-aortic-valve-calcification-targeting-dock2 2026-09-01T16:51:28+00:00 hourly 0.9 https://trial.medpath.com/news/immunic-appoints-chitrang-dave-as-chief-data-and-digital-officer-ahead-of-pivotal-ms-readouts 2026-09-01T16:51:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunic-appoints-chitrang-dave-as-chief-data-and-digital-officer-ahead-of-pivotal-ms-readouts 2026-09-01T16:51:05+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-bill-proposes-12-year-market-exclusivity-for-fda-approved-botanical-drugs 2026-09-01T16:50:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-bill-proposes-12-year-market-exclusivity-for-fda-approved-botanical-drugs 2026-09-01T16:50:57+00:00 hourly 0.9 https://trial.medpath.com/news/children-s-hospital-colorado-launches-sublingual-immunotherapy-program-for-pediatric-food-allergies 2026-09-01T16:50:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/children-s-hospital-colorado-launches-sublingual-immunotherapy-program-for-pediatric-food-allergies 2026-09-01T16:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-juniper-s-jbs-003-hypoxia-tracer-for-radiation-de-escalation-in-hpv-positive-oropharyngeal-cancer 2026-09-01T15:49:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-juniper-s-jbs-003-hypoxia-tracer-for-radiation-de-escalation-in-hpv-positive-oropharyngeal-cancer 2026-09-01T15:49:29+00:00 hourly 0.9 https://trial.medpath.com/news/md-integrations-partners-with-legitscript-to-expedite-telehealth-compliance-certification 2026-09-01T15:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-integrations-partners-with-legitscript-to-expedite-telehealth-compliance-certification 2026-09-01T15:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/bioviva-secures-two-u-s-patents-for-longevity-gene-therapies-targeting-klotho-htert-and-follistatin-344 2026-09-01T15:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioviva-secures-two-u-s-patents-for-longevity-gene-therapies-targeting-klotho-htert-and-follistatin-344 2026-09-01T15:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/stolen-veterinary-euthanasia-drug-poses-extreme-danger-to-maine-community-police-warn 2026-09-01T13:49:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stolen-veterinary-euthanasia-drug-poses-extreme-danger-to-maine-community-police-warn 2026-09-01T13:49:43+00:00 hourly 0.9 https://trial.medpath.com/news/veeva-falcon-safety-automates-adverse-event-intake-across-e2b-compliant-systems 2026-09-01T13:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veeva-falcon-safety-automates-adverse-event-intake-across-e2b-compliant-systems 2026-09-01T13:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/early-onset-bowel-cancer-shows-distinct-biology-and-better-survival-in-liver-only-metastases 2026-09-01T13:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-onset-bowel-cancer-shows-distinct-biology-and-better-survival-in-liver-only-metastases 2026-09-01T13:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-therapeutics-trades-63-below-estimated-fair-value-despite-elevated-p-e-analyst-model-shows 2026-09-01T13:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-therapeutics-trades-63-below-estimated-fair-value-despite-elevated-p-e-analyst-model-shows 2026-09-01T13:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/netramark-appoints-veteran-pharmaceutical-executive-dr-keith-fournier-to-board-of-directors 2026-09-01T12:52:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/netramark-appoints-veteran-pharmaceutical-executive-dr-keith-fournier-to-board-of-directors 2026-09-01T12:52:57+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-expands-health-insurance-to-cut-costs-for-rare-diseases-and-severe-diabetes 2026-09-01T10:53:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-expands-health-insurance-to-cut-costs-for-rare-diseases-and-severe-diabetes 2026-09-01T10:53:39+00:00 hourly 0.9 https://trial.medpath.com/news/epa-reapproval-of-pfas-herbicide-trifludimoxazin-draws-lawsuit-from-three-advocacy-groups 2026-09-01T09:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epa-reapproval-of-pfas-herbicide-trifludimoxazin-draws-lawsuit-from-three-advocacy-groups 2026-09-01T09:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/optiscan-launches-us-head-and-neck-cancer-imaging-study-with-mayo-clinic-to-support-fda-submissions 2026-09-01T09:25:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optiscan-launches-us-head-and-neck-cancer-imaging-study-with-mayo-clinic-to-support-fda-submissions 2026-09-01T09:25:24+00:00 hourly 0.9 https://trial.medpath.com/news/fujirebio-secures-health-canada-licenses-for-blood-based-neurology-assays 2026-09-01T09:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujirebio-secures-health-canada-licenses-for-blood-based-neurology-assays 2026-09-01T09:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/immediate-coronary-angiography-does-not-improve-survival-after-out-of-hospital-cardiac-arrest-without-st-elevation 2026-09-01T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immediate-coronary-angiography-does-not-improve-survival-after-out-of-hospital-cardiac-arrest-without-st-elevation 2026-09-01T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-johnson-johnson-s-imaavy-nipocalimab-aahu-as-first-therapy-for-warm-autoimmune-hemolytic-anemia 2026-09-01T09:16:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-johnson-johnson-s-imaavy-nipocalimab-aahu-as-first-therapy-for-warm-autoimmune-hemolytic-anemia 2026-09-01T09:16:17+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-phase-3-baxhtn-data-confirm-baxdrostat-efficacy-and-safety-in-resistant-hypertension 2026-09-01T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-phase-3-baxhtn-data-confirm-baxdrostat-efficacy-and-safety-in-resistant-hypertension 2026-09-01T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-bristol-myers-pause-autoimmune-car-t-trials-after-inflammatory-safety-signals 2026-09-01T09:14:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-bristol-myers-pause-autoimmune-car-t-trials-after-inflammatory-safety-signals 2026-09-01T09:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/senate-unanimously-passes-kay-hagan-tick-reauthorization-act-as-lyme-cases-hit-record-highs 2026-09-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-unanimously-passes-kay-hagan-tick-reauthorization-act-as-lyme-cases-hit-record-highs 2026-09-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/teva-and-trump-administration-announce-intent-to-reach-agreement-on-affordable-medicines-and-supply-chain-security-for-u-s-medicaid-patients 2026-08-31T21:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-and-trump-administration-announce-intent-to-reach-agreement-on-affordable-medicines-and-supply-chain-security-for-u-s-medicaid-patients 2026-08-31T21:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-appoints-chris-benecchi-as-chief-operating-officer-ahead-of-pivotal-mash-phase-3-readout 2026-08-31T21:48:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventiva-appoints-chris-benecchi-as-chief-operating-officer-ahead-of-pivotal-mash-phase-3-readout 2026-08-31T21:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/arsenalbio-shifts-strategic-focus-to-in-vivo-car-t-cell-therapies-expanding-into-autoimmunity 2026-08-31T21:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arsenalbio-shifts-strategic-focus-to-in-vivo-car-t-cell-therapies-expanding-into-autoimmunity 2026-08-31T21:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-drug-shortages-threaten-lives-as-efforts-to-prevent-them-hit-regulatory-red-tape 2026-08-31T20:53:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-drug-shortages-threaten-lives-as-efforts-to-prevent-them-hit-regulatory-red-tape 2026-08-31T20:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/chile-s-isp-opens-public-consultation-on-national-technovigilance-system-guidance-for-medical-devices 2026-08-31T20:53:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chile-s-isp-opens-public-consultation-on-national-technovigilance-system-guidance-for-medical-devices 2026-08-31T20:53:33+00:00 hourly 0.9 https://trial.medpath.com/news/new-aan-and-ahs-guidelines-expand-pharmacological-options-for-migraine-prevention 2026-08-31T20:52:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-aan-and-ahs-guidelines-expand-pharmacological-options-for-migraine-prevention 2026-08-31T20:52:53+00:00 hourly 0.9 https://trial.medpath.com/news/australia-prepares-world-first-mrna-vaccine-trial-for-children-with-aggressive-brain-tumors 2026-08-31T20:52:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-prepares-world-first-mrna-vaccine-trial-for-children-with-aggressive-brain-tumors 2026-08-31T20:52:43+00:00 hourly 0.9 https://trial.medpath.com/news/two-week-wearable-heart-monitor-after-unexplained-fainting-doubles-arrhythmia-detection-and-halves-one-year-death-rate 2026-08-31T20:52:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-week-wearable-heart-monitor-after-unexplained-fainting-doubles-arrhythmia-detection-and-halves-one-year-death-rate 2026-08-31T20:52:16+00:00 hourly 0.9 https://trial.medpath.com/news/karolinska-institutet-s-center-for-heart-failure-and-arrhythmia-publishes-broad-2026-research-portfolio-spanning-epidemiology-pharmacotherapy-and-outcomes 2026-08-31T20:51:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karolinska-institutet-s-center-for-heart-failure-and-arrhythmia-publishes-broad-2026-research-portfolio-spanning-epidemiology-pharmacotherapy-and-outcomes 2026-08-31T20:51:21+00:00 hourly 0.9 https://trial.medpath.com/news/australia-s-little-penguin-h5n1-vaccination-drive-uses-killed-virus-shot-not-mrna-officials-confirm 2026-08-31T18:49:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-s-little-penguin-h5n1-vaccination-drive-uses-killed-virus-shot-not-mrna-officials-confirm 2026-08-31T18:49:20+00:00 hourly 0.9 https://trial.medpath.com/news/drug-repurposing-screen-identifies-dopamine-signaling-and-cox-inhibition-as-candidate-therapeutic-pathways-for-piga-cdg 2026-08-31T18:49:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-repurposing-screen-identifies-dopamine-signaling-and-cox-inhibition-as-candidate-therapeutic-pathways-for-piga-cdg 2026-08-31T18:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/trump-expected-to-announce-new-drug-pricing-deals-with-nearly-a-dozen-drugmakers 2026-08-31T18:48:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-expected-to-announce-new-drug-pricing-deals-with-nearly-a-dozen-drugmakers 2026-08-31T18:48:50+00:00 hourly 0.9 https://trial.medpath.com/news/anonymous-donor-establishes-endowed-funds-to-advance-concussion-care-and-research-at-stony-brook-medicine 2026-08-31T18:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anonymous-donor-establishes-endowed-funds-to-advance-concussion-care-and-research-at-stony-brook-medicine 2026-08-31T18:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-cabozantinib-crystalline-salt-patents-preserving-exelixis-market-exclusivity-to-2030 2026-08-31T18:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-upholds-cabozantinib-crystalline-salt-patents-preserving-exelixis-market-exclusivity-to-2030 2026-08-31T18:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-launches-first-ready-to-feed-infant-formula-made-with-whole-milk-in-the-u-s 2026-08-31T17:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-launches-first-ready-to-feed-infant-formula-made-with-whole-milk-in-the-u-s 2026-08-31T17:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/how-to-read-a-biotech-clinical-trial-result-p-values-endpoints-and-investor-implications 2026-08-31T16:52:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-to-read-a-biotech-clinical-trial-result-p-values-endpoints-and-investor-implications 2026-08-31T16:52:08+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-taltz-plus-zepbound-shows-durable-one-year-benefits-in-psoriatic-disease-and-obesity 2026-08-31T16:50:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-taltz-plus-zepbound-shows-durable-one-year-benefits-in-psoriatic-disease-and-obesity 2026-08-31T16:50:35+00:00 hourly 0.9 https://trial.medpath.com/news/veloxis-doses-first-patient-in-phase-2-rengevity-201-trial-of-pegrizeprument-for-kidney-transplant-rejection-prevention 2026-08-31T16:49:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veloxis-doses-first-patient-in-phase-2-rengevity-201-trial-of-pegrizeprument-for-kidney-transplant-rejection-prevention 2026-08-31T16:49:10+00:00 hourly 0.9 https://trial.medpath.com/news/biotecanada-announces-2026-gold-leaf-award-winners-recognizing-excellence-across-canada-s-biotechnology-ecosystem 2026-08-31T15:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotecanada-announces-2026-gold-leaf-award-winners-recognizing-excellence-across-canada-s-biotechnology-ecosystem 2026-08-31T15:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/fareon-links-microtesla-magnetic-therapy-to-reduced-brain-age-and-repair-biomarkers-in-long-covid-cognitive-impairment 2026-08-31T15:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fareon-links-microtesla-magnetic-therapy-to-reduced-brain-age-and-repair-biomarkers-in-long-covid-cognitive-impairment 2026-08-31T15:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/oligomerix-appoints-cara-cassino-m-d-as-interim-president-and-ceo-to-advance-olx-07010-in-alzheimer-s-disease 2026-08-31T15:48:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oligomerix-appoints-cara-cassino-m-d-as-interim-president-and-ceo-to-advance-olx-07010-in-alzheimer-s-disease 2026-08-31T15:48:34+00:00 hourly 0.9 https://trial.medpath.com/news/emmaus-life-sciences-cedars-sinai-sign-option-deal-to-advance-l-glutamine-in-pancreatic-cancer-after-phase-1-tumor-shrinkage-data 2026-08-31T15:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emmaus-life-sciences-cedars-sinai-sign-option-deal-to-advance-l-glutamine-in-pancreatic-cancer-after-phase-1-tumor-shrinkage-data 2026-08-31T15:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-of-397-pediatric-mental-health-trials-finds-women-minoritized-groups-systematically-under-represented 2026-08-31T14:51:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-of-397-pediatric-mental-health-trials-finds-women-minoritized-groups-systematically-under-represented 2026-08-31T14:51:37+00:00 hourly 0.9 https://trial.medpath.com/news/one-year-exercise-intervention-cuts-atrial-fibrillation-burden-by-45-in-nexaf-trial 2026-08-31T14:51:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-year-exercise-intervention-cuts-atrial-fibrillation-burden-by-45-in-nexaf-trial 2026-08-31T14:51:06+00:00 hourly 0.9 https://trial.medpath.com/news/angptl3-inhibitors-market-poised-to-reach-3-48-billion-by-2035-as-pipeline-diversifies-beyond-monoclonal-antibodies 2026-08-31T14:50:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angptl3-inhibitors-market-poised-to-reach-3-48-billion-by-2035-as-pipeline-diversifies-beyond-monoclonal-antibodies 2026-08-31T14:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/cymbiotika-partners-with-hundred-health-to-deliver-personalized-biomarker-driven-wellness-plans 2026-08-31T14:50:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cymbiotika-partners-with-hundred-health-to-deliver-personalized-biomarker-driven-wellness-plans 2026-08-31T14:50:13+00:00 hourly 0.9 https://trial.medpath.com/news/national-conference-on-quantum-biotechnology-charts-india-s-path-in-quantum-enabled-life-sciences 2026-08-31T14:49:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-conference-on-quantum-biotechnology-charts-india-s-path-in-quantum-enabled-life-sciences 2026-08-31T14:49:56+00:00 hourly 0.9 https://trial.medpath.com/news/routine-invasive-treatment-should-not-be-replaced-by-selective-care-in-older-nstemi-patients-evaold-trial-finds 2026-08-31T14:49:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/routine-invasive-treatment-should-not-be-replaced-by-selective-care-in-older-nstemi-patients-evaold-trial-finds 2026-08-31T14:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/xyra-doses-first-european-patient-in-phase-2-3-harbor-af-study-of-budiodarone-for-atrial-fibrillation 2026-08-31T13:50:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xyra-doses-first-european-patient-in-phase-2-3-harbor-af-study-of-budiodarone-for-atrial-fibrillation 2026-08-31T13:50:35+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-secures-exclusive-rights-to-her2-bispecific-adc-tqb2102-across-seven-emerging-markets 2026-08-31T13:50:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cipla-secures-exclusive-rights-to-her2-bispecific-adc-tqb2102-across-seven-emerging-markets 2026-08-31T13:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-acquires-commercialization-rights-to-ferring-s-rebyota-and-clenpiq-in-transformational-gi-repositioning 2026-08-31T13:49:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-acquires-commercialization-rights-to-ferring-s-rebyota-and-clenpiq-in-transformational-gi-repositioning 2026-08-31T13:49:17+00:00 hourly 0.9 https://trial.medpath.com/news/acto-ceo-parth-khanna-ai-trust-in-pharma-comes-down-to-compliant-plus-capable 2026-08-31T13:49:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acto-ceo-parth-khanna-ai-trust-in-pharma-comes-down-to-compliant-plus-capable 2026-08-31T13:49:15+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-receives-fda-breakthrough-device-designation-for-lungfit-go-in-ntm-pd 2026-08-31T13:49:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-air-receives-fda-breakthrough-device-designation-for-lungfit-go-in-ntm-pd 2026-08-31T13:49:10+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-to-acquire-merida-biosciences-for-up-to-2-88-billion-adding-novel-autoantibody-targeting-pipeline 2026-08-31T12:52:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-to-acquire-merida-biosciences-for-up-to-2-88-billion-adding-novel-autoantibody-targeting-pipeline 2026-08-31T12:52:35+00:00 hourly 0.9 https://trial.medpath.com/news/esc-issues-first-dedicated-international-guidelines-on-cardiac-rehabilitation 2026-08-31T12:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esc-issues-first-dedicated-international-guidelines-on-cardiac-rehabilitation 2026-08-31T12:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/ugandan-firm-dei-biopharma-files-seven-us-patents-for-mrna-cancer-vaccines-targeting-recurrence 2026-08-31T12:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ugandan-firm-dei-biopharma-files-seven-us-patents-for-mrna-cancer-vaccines-targeting-recurrence 2026-08-31T12:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-launches-next-generation-of-global-trial-connect-to-streamline-clinical-trial-operations 2026-08-31T12:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-launches-next-generation-of-global-trial-connect-to-streamline-clinical-trial-operations 2026-08-31T12:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/africa-must-convert-biotechnology-into-wealth-not-just-export-raw-biomass-expert-argues 2026-08-31T12:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/africa-must-convert-biotechnology-into-wealth-not-just-export-raw-biomass-expert-argues 2026-08-31T12:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/adaptyv-raises-40m-series-a-to-scale-automated-protein-validation-labs-for-ai-driven-drug-discovery 2026-08-31T12:30:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptyv-raises-40m-series-a-to-scale-automated-protein-validation-labs-for-ai-driven-drug-discovery 2026-08-31T12:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/andera-partners-olivier-litzka-on-picking-biotech-winners-beyond-the-hype-cycle 2026-08-31T12:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andera-partners-olivier-litzka-on-picking-biotech-winners-beyond-the-hype-cycle 2026-08-31T12:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/metag1-launches-controlled-scientific-discussion-platform-for-pharma-and-life-sciences 2026-08-31T12:30:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metag1-launches-controlled-scientific-discussion-platform-for-pharma-and-life-sciences 2026-08-31T12:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-announces-successful-fda-type-c-meeting-for-ide849-dll3-top1-adc-in-extensive-stage-small-cell-lung-cancer 2026-08-31T12:30:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-announces-successful-fda-type-c-meeting-for-ide849-dll3-top1-adc-in-extensive-stage-small-cell-lung-cancer 2026-08-31T12:30:10+00:00 hourly 0.9 https://trial.medpath.com/news/biotak-score-identifies-broken-heart-syndrome-before-invasive-catheterization 2026-08-31T12:29:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotak-score-identifies-broken-heart-syndrome-before-invasive-catheterization 2026-08-31T12:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/nurexone-advances-exosome-based-exopten-toward-clinical-development-for-spinal-cord-and-optic-nerve-regeneration 2026-08-31T12:27:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurexone-advances-exosome-based-exopten-toward-clinical-development-for-spinal-cord-and-optic-nerve-regeneration 2026-08-31T12:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/hkbu-inaugural-cxc-session-spotlights-autophagy-as-new-hope-for-brain-diseases 2026-08-31T12:26:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hkbu-inaugural-cxc-session-spotlights-autophagy-as-new-hope-for-brain-diseases 2026-08-31T12:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/adolescent-binge-drinking-causes-lasting-astrocyte-synaptic-disruption-pointing-to-new-treatment-targets 2026-08-31T12:26:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adolescent-binge-drinking-causes-lasting-astrocyte-synaptic-disruption-pointing-to-new-treatment-targets 2026-08-31T12:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/ireland-establishes-clinical-trials-advisory-council-to-transform-national-clinical-research-landscape 2026-08-31T12:24:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ireland-establishes-clinical-trials-advisory-council-to-transform-national-clinical-research-landscape 2026-08-31T12:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-secures-20-royalty-on-ascendis-yuviwel-in-global-patent-settlement 2026-08-31T12:23:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-secures-20-royalty-on-ascendis-yuviwel-in-global-patent-settlement 2026-08-31T12:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/ena-respiratory-secures-aud-2-98-million-to-advance-inna-051-antiviral-nasal-spray-into-asthma-trial 2026-08-31T12:23:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ena-respiratory-secures-aud-2-98-million-to-advance-inna-051-antiviral-nasal-spray-into-asthma-trial 2026-08-31T12:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/royal-perth-hospital-becomes-first-australian-hospital-licensed-to-manufacture-til-therapies-for-clinical-trials 2026-08-31T12:23:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royal-perth-hospital-becomes-first-australian-hospital-licensed-to-manufacture-til-therapies-for-clinical-trials 2026-08-31T12:23:02+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-probiotic-carriers-emerge-as-living-drug-factories-for-tumor-targeted-therapy 2026-08-31T12:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-probiotic-carriers-emerge-as-living-drug-factories-for-tumor-targeted-therapy 2026-08-31T12:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/roche-selects-singapore-as-global-pilot-site-for-precision-medicine-in-cancer 2026-08-31T12:19:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-selects-singapore-as-global-pilot-site-for-precision-medicine-in-cancer 2026-08-31T12:19:46+00:00 hourly 0.9 https://trial.medpath.com/news/leios-therapeutics-licenses-10xb-101-to-china-medical-system-for-focal-fat-reduction 2026-08-31T12:19:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leios-therapeutics-licenses-10xb-101-to-china-medical-system-for-focal-fat-reduction 2026-08-31T12:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/bio-visu-s-u-s-sales-surge-past-7-billion-won-as-ecm-skin-booster-business-fuels-global-expansion 2026-08-31T12:19:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-visu-s-u-s-sales-surge-past-7-billion-won-as-ecm-skin-booster-business-fuels-global-expansion 2026-08-31T12:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/cna-s-by-your-side-documents-the-daily-realities-of-caregiving-for-rare-diseases-and-neurodegenerative-conditions 2026-08-31T12:19:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cna-s-by-your-side-documents-the-daily-realities-of-caregiving-for-rare-diseases-and-neurodegenerative-conditions 2026-08-31T12:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/subsidised-access-to-columvi-glofitamab-now-available-for-relapsed-refractory-dlbcl-patients-in-singapore 2026-08-31T12:19:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subsidised-access-to-columvi-glofitamab-now-available-for-relapsed-refractory-dlbcl-patients-in-singapore 2026-08-31T12:19:40+00:00 hourly 0.9 https://trial.medpath.com/news/christus-health-opens-36-million-cancer-center-in-longview-to-address-east-texas-cancer-burden 2026-08-31T12:19:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/christus-health-opens-36-million-cancer-center-in-longview-to-address-east-texas-cancer-burden 2026-08-31T12:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/onconic-therapeutics-secures-u-s-patent-for-nesuparib-crystalline-form-and-manufacturing-method 2026-08-31T12:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onconic-therapeutics-secures-u-s-patent-for-nesuparib-crystalline-form-and-manufacturing-method 2026-08-31T12:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/aptone-finalizes-fda-phase-3-protocol-for-orphan-drug-gpc-100-a-rapid-acting-stem-cell-mobilizer 2026-08-31T12:18:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptone-finalizes-fda-phase-3-protocol-for-orphan-drug-gpc-100-a-rapid-acting-stem-cell-mobilizer 2026-08-31T12:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/data4life-and-monash-health-partner-to-advance-clinical-research-with-open-source-rwd-platforms 2026-08-31T12:16:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/data4life-and-monash-health-partner-to-advance-clinical-research-with-open-source-rwd-platforms 2026-08-31T12:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/pakistan-to-honor-nurse-who-rescued-sole-survivor-of-hospital-nursery-fire-that-killed-14-newborns 2026-08-31T12:15:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pakistan-to-honor-nurse-who-rescued-sole-survivor-of-hospital-nursery-fire-that-killed-14-newborns 2026-08-31T12:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/biomedit-acquires-folium-science-to-expand-programmable-veterinary-biologics-platform 2026-08-31T12:15:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomedit-acquires-folium-science-to-expand-programmable-veterinary-biologics-platform 2026-08-31T12:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/kano-state-launches-special-committee-to-contain-diphtheria-outbreak 2026-08-31T12:14:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kano-state-launches-special-committee-to-contain-diphtheria-outbreak 2026-08-31T12:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/ai-assisted-digital-pathology-poised-to-transform-hematologic-malignancy-diagnosis 2026-08-31T12:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-assisted-digital-pathology-poised-to-transform-hematologic-malignancy-diagnosis 2026-08-31T12:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-bacteria-recycle-co2-in-situ-to-boost-succinic-acid-production-to-near-industrial-levels 2026-08-31T12:12:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-bacteria-recycle-co2-in-situ-to-boost-succinic-acid-production-to-near-industrial-levels 2026-08-31T12:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/kanawha-valley-fellowship-home-advances-phase-ii-expansion-to-extend-sober-living-for-men-in-recovery 2026-08-31T12:10:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kanawha-valley-fellowship-home-advances-phase-ii-expansion-to-extend-sober-living-for-men-in-recovery 2026-08-31T12:10:51+00:00 hourly 0.9 https://trial.medpath.com/news/mckesson-data-breach-shinyhunters-claims-284-million-records-stolen-demands-55-million-ransom 2026-08-31T12:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mckesson-data-breach-shinyhunters-claims-284-million-records-stolen-demands-55-million-ransom 2026-08-31T12:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/h-heft-trial-finds-no-benefit-for-hydralazine-isosorbide-dinitrate-in-heart-failure 2026-08-31T12:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/h-heft-trial-finds-no-benefit-for-hydralazine-isosorbide-dinitrate-in-heart-failure 2026-08-31T12:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-presents-new-data-at-esc-congress-2026-reinforcing-rnai-powered-ttr-silencing-in-attr-cm-and-hypertension 2026-08-31T12:05:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-presents-new-data-at-esc-congress-2026-reinforcing-rnai-powered-ttr-silencing-in-attr-cm-and-hypertension 2026-08-31T12:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/fire-at-kyiv-s-sp-hall-business-center-novartis-office-among-those-affected 2026-08-31T12:03:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fire-at-kyiv-s-sp-hall-business-center-novartis-office-among-those-affected 2026-08-31T12:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/nurse-coordinated-collaborative-care-improves-heart-failure-outcomes-in-time-hf-trial 2026-08-31T11:59:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurse-coordinated-collaborative-care-improves-heart-failure-outcomes-in-time-hf-trial 2026-08-31T11:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/radical-pc-2-specialist-referral-improves-cholesterol-control-but-not-cardiovascular-events-in-prostate-cancer-patients 2026-08-31T11:58:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radical-pc-2-specialist-referral-improves-cholesterol-control-but-not-cardiovascular-events-in-prostate-cancer-patients 2026-08-31T11:58:37+00:00 hourly 0.9 https://trial.medpath.com/news/north-carolina-warns-mobile-petting-zoo-visitors-of-rabies-exposure-after-baby-goats-test-positive 2026-08-31T11:55:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/north-carolina-warns-mobile-petting-zoo-visitors-of-rabies-exposure-after-baby-goats-test-positive 2026-08-31T11:55:46+00:00 hourly 0.9 https://trial.medpath.com/news/nanopore-sensor-technology-enables-early-detection-of-parkinson-s-and-als-biomarkers 2026-08-31T11:55:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanopore-sensor-technology-enables-early-detection-of-parkinson-s-and-als-biomarkers 2026-08-31T11:55:44+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-supreme-court-presses-fssai-on-red-hexagon-front-of-pack-warning-labels-for-hfss-foods 2026-08-31T11:55:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-supreme-court-presses-fssai-on-red-hexagon-front-of-pack-warning-labels-for-hfss-foods 2026-08-31T11:55:43+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-valneva-lyme-vaccine-nears-fda-filing-as-court-injunction-freezes-the-panel-that-would-guide-its-rollout 2026-08-31T11:55:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-valneva-lyme-vaccine-nears-fda-filing-as-court-injunction-freezes-the-panel-that-would-guide-its-rollout 2026-08-31T11:55:02+00:00 hourly 0.9 https://trial.medpath.com/news/dubai-ruler-funds-zolgensma-gene-therapy-for-children-with-spinal-muscular-atrophy 2026-08-31T11:52:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dubai-ruler-funds-zolgensma-gene-therapy-for-children-with-spinal-muscular-atrophy 2026-08-31T11:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/immediate-evolocumab-after-heart-attack-improves-ldl-c-goal-attainment-but-not-early-cardiovascular-outcomes 2026-08-31T11:49:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immediate-evolocumab-after-heart-attack-improves-ldl-c-goal-attainment-but-not-early-cardiovascular-outcomes 2026-08-31T11:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/arizona-boy-11-diagnosed-with-idiopathic-multicentric-castleman-disease-after-sudden-chest-and-back-pain 2026-08-31T11:47:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arizona-boy-11-diagnosed-with-idiopathic-multicentric-castleman-disease-after-sudden-chest-and-back-pain 2026-08-31T11:47:30+00:00 hourly 0.9 https://trial.medpath.com/news/dutch-drug-institute-issues-red-alert-over-potentially-fatal-trump-shaped-ecstasy-pills-containing-pmma 2026-08-31T11:46:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dutch-drug-institute-issues-red-alert-over-potentially-fatal-trump-shaped-ecstasy-pills-containing-pmma 2026-08-31T11:46:55+00:00 hourly 0.9 https://trial.medpath.com/news/australia-expands-pbs-subsidy-for-keytruda-to-cover-ovarian-bile-duct-and-merkel-cell-cancers 2026-08-31T11:46:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-expands-pbs-subsidy-for-keytruda-to-cover-ovarian-bile-duct-and-merkel-cell-cancers 2026-08-31T11:46:18+00:00 hourly 0.9 https://trial.medpath.com/news/codis-completes-acquisition-of-catalent-s-nottingham-facility-creating-europe-s-most-comprehensive-spray-dry-network 2026-08-31T11:46:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/codis-completes-acquisition-of-catalent-s-nottingham-facility-creating-europe-s-most-comprehensive-spray-dry-network 2026-08-31T11:46:15+00:00 hourly 0.9 https://trial.medpath.com/news/vijay-pande-launches-vzvc-a-concentrated-ai-biotech-fund-after-building-a16z-s-4-billion-bio-practice 2026-08-31T11:46:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vijay-pande-launches-vzvc-a-concentrated-ai-biotech-fund-after-building-a16z-s-4-billion-bio-practice 2026-08-31T11:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/blood-cancer-patient-runs-parkrun-to-boost-stem-cell-donor-registration 2026-08-31T11:46:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-cancer-patient-runs-parkrun-to-boost-stem-cell-donor-registration 2026-08-31T11:46:04+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-women-with-hypoactive-sexual-desire-disorder-still-engage-in-mercy-sex-two-to-three-times-monthly 2026-08-31T11:46:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-women-with-hypoactive-sexual-desire-disorder-still-engage-in-mercy-sex-two-to-three-times-monthly 2026-08-31T11:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/icds-may-benefit-younger-patients-with-mild-to-moderate-heart-dysfunction-cmr-guide-trial-finds 2026-08-31T11:45:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icds-may-benefit-younger-patients-with-mild-to-moderate-heart-dysfunction-cmr-guide-trial-finds 2026-08-31T11:45:08+00:00 hourly 0.9 https://trial.medpath.com/news/who-designates-south-korea-s-ghc-as-world-s-first-collaborating-center-for-medical-product-regulatory-system-training 2026-08-31T11:44:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-designates-south-korea-s-ghc-as-world-s-first-collaborating-center-for-medical-product-regulatory-system-training 2026-08-31T11:44:32+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-presents-baseline-characteristics-from-phase-2-genephit-trial-of-umiposgene-parvec-in-heart-failure 2026-08-31T11:44:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/askbio-presents-baseline-characteristics-from-phase-2-genephit-trial-of-umiposgene-parvec-in-heart-failure 2026-08-31T11:44:05+00:00 hourly 0.9 https://trial.medpath.com/news/world-radiotherapy-awareness-day-highlights-growing-global-demand-and-workforce-shortages 2026-08-31T11:43:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-radiotherapy-awareness-day-highlights-growing-global-demand-and-workforce-shortages 2026-08-31T11:43:45+00:00 hourly 0.9 https://trial.medpath.com/news/baldness-drugs-emerge-as-wall-street-s-next-goldmine-as-novel-treatments-near-market 2026-08-31T11:41:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baldness-drugs-emerge-as-wall-street-s-next-goldmine-as-novel-treatments-near-market 2026-08-31T11:41:40+00:00 hourly 0.9 https://trial.medpath.com/news/total-body-pet-ct-twins-accelerate-research-and-cut-radiation-dose-at-king-s-college-london 2026-08-31T11:41:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/total-body-pet-ct-twins-accelerate-research-and-cut-radiation-dose-at-king-s-college-london 2026-08-31T11:41:28+00:00 hourly 0.9 https://trial.medpath.com/news/global-type-1-diabetes-burden-projected-to-rise-29-by-2049-reaching-12-1-million-cases 2026-08-31T11:38:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-type-1-diabetes-burden-projected-to-rise-29-by-2049-reaching-12-1-million-cases 2026-08-31T11:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasensitive-salivary-cytokine-profiling-reveals-distinct-immune-signatures-in-dental-caries 2026-08-31T11:38:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultrasensitive-salivary-cytokine-profiling-reveals-distinct-immune-signatures-in-dental-caries 2026-08-31T11:38:49+00:00 hourly 0.9 https://trial.medpath.com/news/kelley-wolf-reveals-breakthrough-drug-induced-mania-with-psychosis-diagnosis-one-year-after-mental-health-crisis 2026-08-31T11:38:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelley-wolf-reveals-breakthrough-drug-induced-mania-with-psychosis-diagnosis-one-year-after-mental-health-crisis 2026-08-31T11:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-experimental-and-computational-exploration-of-18-naphthyridine-hydrazones-published-under-open-access 2026-08-31T11:38:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-experimental-and-computational-exploration-of-18-naphthyridine-hydrazones-published-under-open-access 2026-08-31T11:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/bengaluru-peptide-party-cancelled-after-karnataka-fda-raises-regulatory-and-safety-concerns 2026-08-31T11:38:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bengaluru-peptide-party-cancelled-after-karnataka-fda-raises-regulatory-and-safety-concerns 2026-08-31T11:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/a-close-trial-antiplatelet-therapy-after-stent-implantation-requires-personalization 2026-08-31T11:38:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-close-trial-antiplatelet-therapy-after-stent-implantation-requires-personalization 2026-08-31T11:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/iowa-launches-i-beacon-program-to-expand-24-7-opioid-treatment-access-statewide 2026-08-31T11:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iowa-launches-i-beacon-program-to-expand-24-7-opioid-treatment-access-statewide 2026-08-31T11:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/poet-ii-trial-cuts-antibiotic-duration-by-two-weeks-in-left-sided-infective-endocarditis-without-compromising-safety 2026-08-31T11:37:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poet-ii-trial-cuts-antibiotic-duration-by-two-weeks-in-left-sided-infective-endocarditis-without-compromising-safety 2026-08-31T11:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/atorvastatin-cuts-major-cardiovascular-events-by-30-in-healthy-adults-over-70-staree-trial-finds 2026-08-31T11:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atorvastatin-cuts-major-cardiovascular-events-by-30-in-healthy-adults-over-70-staree-trial-finds 2026-08-31T11:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/react-study-early-imaging-detects-silent-atherosclerosis-missed-by-conventional-risk-assessment 2026-08-31T11:33:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/react-study-early-imaging-detects-silent-atherosclerosis-missed-by-conventional-risk-assessment 2026-08-31T11:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/tranquility-pacibekitug-produces-sustained-reductions-in-inflammatory-markers-in-ckd-patients 2026-08-31T11:33:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tranquility-pacibekitug-produces-sustained-reductions-in-inflammatory-markers-in-ckd-patients 2026-08-31T11:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-juul-2-e-cigarette-device-and-tobacco-and-menthol-flavored-pods 2026-08-31T11:28:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-juul-2-e-cigarette-device-and-tobacco-and-menthol-flavored-pods 2026-08-31T11:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-reports-65-2-complete-response-rate-in-phase-ii-bladder-cancer-study-plans-nda-filing-in-3q2026 2026-08-31T11:27:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theralase-reports-65-2-complete-response-rate-in-phase-ii-bladder-cancer-study-plans-nda-filing-in-3q2026 2026-08-31T11:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/ai-models-accelerate-rare-disease-diagnosis-at-boston-children-s-and-cheo 2026-08-31T11:26:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-models-accelerate-rare-disease-diagnosis-at-boston-children-s-and-cheo 2026-08-31T11:26:59+00:00 hourly 0.9 https://trial.medpath.com/news/specialized-lung-vein-cells-actively-drive-pulmonary-fibrosis-revealing-a-new-therapeutic-target 2026-08-31T11:25:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/specialized-lung-vein-cells-actively-drive-pulmonary-fibrosis-revealing-a-new-therapeutic-target 2026-08-31T11:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/dea-revokes-opioid-prescribing-privileges-of-sports-nurse-who-served-elite-athletes 2026-08-31T11:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-revokes-opioid-prescribing-privileges-of-sports-nurse-who-served-elite-athletes 2026-08-31T11:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-mimrylo-rusfertide-first-in-class-hepcidin-mimetic-for-polycythemia-vera 2026-08-31T11:24:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-mimrylo-rusfertide-first-in-class-hepcidin-mimetic-for-polycythemia-vera 2026-08-31T11:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/jefferson-county-launches-leave-behind-program-to-distribute-overdose-response-kits-and-connect-at-risk-individuals-to-treatment 2026-08-31T11:23:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jefferson-county-launches-leave-behind-program-to-distribute-overdose-response-kits-and-connect-at-risk-individuals-to-treatment 2026-08-31T11:23:21+00:00 hourly 0.9 https://trial.medpath.com/news/canada-recruits-64-top-researchers-including-48-from-us-institutions-amid-federal-funding-turmoil 2026-08-31T11:23:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-recruits-64-top-researchers-including-48-from-us-institutions-amid-federal-funding-turmoil 2026-08-31T11:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/germline-variants-define-prognostic-subgroups-in-therapy-related-myeloid-neoplasms 2026-08-31T11:23:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/germline-variants-define-prognostic-subgroups-in-therapy-related-myeloid-neoplasms 2026-08-31T11:23:11+00:00 hourly 0.9 https://trial.medpath.com/news/nanocarriers-identify-prox1-as-a-new-gene-therapy-target-for-glaucoma 2026-08-31T11:22:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanocarriers-identify-prox1-as-a-new-gene-therapy-target-for-glaucoma 2026-08-31T11:22:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-untitled-letter-to-alar-pharmaceuticals-over-promotion-of-unapproved-ketamine-drug-ala-3000 2026-08-31T11:22:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-untitled-letter-to-alar-pharmaceuticals-over-promotion-of-unapproved-ketamine-drug-ala-3000 2026-08-31T11:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/electra-therapeutics-launches-phase-1-trial-of-ela822-a-sirpg-specific-antibody-for-chronic-t-cell-mediated-diseases 2026-08-31T11:21:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/electra-therapeutics-launches-phase-1-trial-of-ela822-a-sirpg-specific-antibody-for-chronic-t-cell-mediated-diseases 2026-08-31T11:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/survey-finds-96-of-multiple-myeloma-patients-want-a-role-in-treatment-decisions-yet-most-have-never-heard-of-shared-decision-making 2026-08-31T11:21:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survey-finds-96-of-multiple-myeloma-patients-want-a-role-in-treatment-decisions-yet-most-have-never-heard-of-shared-decision-making 2026-08-31T11:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/multi-omics-maps-compartment-specific-gut-kidney-axis-in-diabetic-kidney-disease-prioritizing-caffeic-acid-and-naringenin-chalcone 2026-08-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-omics-maps-compartment-specific-gut-kidney-axis-in-diabetic-kidney-disease-prioritizing-caffeic-acid-and-naringenin-chalcone 2026-08-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bombay-high-court-pulls-up-maharashtra-fda-over-cipla-drug-licence-cancellation 2026-08-28T19:49:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bombay-high-court-pulls-up-maharashtra-fda-over-cipla-drug-licence-cancellation 2026-08-28T19:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/xylitol-a-common-sweetener-linked-to-increased-risk-of-heart-attack-and-stroke-in-large-observational-study 2026-08-28T19:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xylitol-a-common-sweetener-linked-to-increased-risk-of-heart-attack-and-stroke-in-large-observational-study 2026-08-28T19:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/cytoniche-expands-u-s-fda-regulatory-filings-for-3d-recomtrix-recombinant-collagen-microcarriers 2026-08-28T19:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytoniche-expands-u-s-fda-regulatory-filings-for-3d-recomtrix-recombinant-collagen-microcarriers 2026-08-28T19:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/bioxcel-therapeutics-files-chapter-11-lines-up-125m-teva-stalking-horse-asset-sale 2026-08-28T18:49:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxcel-therapeutics-files-chapter-11-lines-up-125m-teva-stalking-horse-asset-sale 2026-08-28T18:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/being-first-in-drug-discovery-tracing-the-origins-of-synthetic-medicines 2026-08-28T17:49:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/being-first-in-drug-discovery-tracing-the-origins-of-synthetic-medicines 2026-08-28T17:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/ausperbio-completes-120-million-series-c-to-advance-ahb-137-toward-commercialization-in-chronic-hepatitis-b 2026-08-28T17:49:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ausperbio-completes-120-million-series-c-to-advance-ahb-137-toward-commercialization-in-chronic-hepatitis-b 2026-08-28T17:49:20+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-to-terminate-mid-stage-trial-of-mrna-cancer-vaccine-autogene-cevumeran-in-colorectal-cancer 2026-08-28T17:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-to-terminate-mid-stage-trial-of-mrna-cancer-vaccine-autogene-cevumeran-in-colorectal-cancer 2026-08-28T17:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-links-30-iv-glutathione-reactions-to-single-medisca-ingredient-lot-used-by-compounding-pharmacies 2026-08-28T16:53:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-links-30-iv-glutathione-reactions-to-single-medisca-ingredient-lot-used-by-compounding-pharmacies 2026-08-28T16:53:31+00:00 hourly 0.9 https://trial.medpath.com/news/tulane-university-launches-500-million-effort-to-transform-charity-hospital-into-a-biomedical-research-hub 2026-08-28T16:53:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tulane-university-launches-500-million-effort-to-transform-charity-hospital-into-a-biomedical-research-hub 2026-08-28T16:53:19+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-terminates-phase-2-trial-of-autogene-cevumeran-in-resected-colorectal-cancer 2026-08-28T16:51:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-terminates-phase-2-trial-of-autogene-cevumeran-in-resected-colorectal-cancer 2026-08-28T16:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/us-secures-cobalt-60-removed-from-guatemala-to-eliminate-dirty-bomb-risk 2026-08-28T15:49:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-secures-cobalt-60-removed-from-guatemala-to-eliminate-dirty-bomb-risk 2026-08-28T15:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/precision-psychiatry-aims-to-match-schizophrenia-patients-with-tailored-medicines 2026-08-28T15:49:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-psychiatry-aims-to-match-schizophrenia-patients-with-tailored-medicines 2026-08-28T15:49:39+00:00 hourly 0.9 https://trial.medpath.com/news/igel-expands-endpoint-options-for-healthcare-and-industrial-environments-with-teguar-hardware 2026-08-28T15:48:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igel-expands-endpoint-options-for-healthcare-and-industrial-environments-with-teguar-hardware 2026-08-28T15:48:43+00:00 hourly 0.9 https://trial.medpath.com/news/formosa-pharmaceuticals-files-cta-for-tsy-110-a-first-in-class-adc-biosimilar-targeting-her2-positive-breast-cancer 2026-08-28T14:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formosa-pharmaceuticals-files-cta-for-tsy-110-a-first-in-class-adc-biosimilar-targeting-her2-positive-breast-cancer 2026-08-28T14:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/teva-bids-to-acquire-bioxcel-s-dexmedetomidine-sublingual-film-for-at-home-agitation-treatment 2026-08-28T14:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-bids-to-acquire-bioxcel-s-dexmedetomidine-sublingual-film-for-at-home-agitation-treatment 2026-08-28T14:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/jubilant-generics-receives-105-5-crore-gst-show-cause-notice-from-uttarakhand-authorities 2026-08-28T14:48:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jubilant-generics-receives-105-5-crore-gst-show-cause-notice-from-uttarakhand-authorities 2026-08-28T14:48:14+00:00 hourly 0.9 https://trial.medpath.com/news/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-through-ai-powered-simulation 2026-08-28T14:48:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-through-ai-powered-simulation 2026-08-28T14:48:11+00:00 hourly 0.9 https://trial.medpath.com/news/asieris-launches-cevira-world-s-first-non-invasive-treatment-for-precancerous-cervical-lesions 2026-08-28T13:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asieris-launches-cevira-world-s-first-non-invasive-treatment-for-precancerous-cervical-lesions 2026-08-28T13:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/self-assembled-a-helical-peptide-nanopores-enable-ultrasensitive-charge-selective-detection-of-parkinson-s-a-synuclein-variants 2026-08-28T13:48:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/self-assembled-a-helical-peptide-nanopores-enable-ultrasensitive-charge-selective-detection-of-parkinson-s-a-synuclein-variants 2026-08-28T13:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-opens-182000-square-foot-research-center-advancing-32-billion-u-s-r-d-and-manufacturing-investment 2026-08-28T12:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-opens-182000-square-foot-research-center-advancing-32-billion-u-s-r-d-and-manufacturing-investment 2026-08-28T12:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/transfyr-launches-physical-ai-platform-for-science-with-25m-seed-funding 2026-08-28T12:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transfyr-launches-physical-ai-platform-for-science-with-25m-seed-funding 2026-08-28T12:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-and-huadong-medicine-expand-partnership-to-co-develop-next-generation-antibody-drug-conjugates 2026-08-28T11:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-and-huadong-medicine-expand-partnership-to-co-develop-next-generation-antibody-drug-conjugates 2026-08-28T11:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-marine-bacteria-accelerate-rock-weathering-for-atmospheric-carbon-removal 2026-08-28T09:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-marine-bacteria-accelerate-rock-weathering-for-atmospheric-carbon-removal 2026-08-28T09:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/heartflow-ffrct-analysis-cuts-unnecessary-invasive-heart-procedures-by-44-in-government-funded-fusion-trial 2026-08-28T06:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heartflow-ffrct-analysis-cuts-unnecessary-invasive-heart-procedures-by-44-in-government-funded-fusion-trial 2026-08-28T06:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-trna-restores-full-length-proteins-in-cystic-fibrosis-models-offering-a-common-strategy-for-thousands-of-genetic-diseases 2026-08-28T04:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-trna-restores-full-length-proteins-in-cystic-fibrosis-models-offering-a-common-strategy-for-thousands-of-genetic-diseases 2026-08-28T04:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/rayzebio-announces-173-million-investment-to-expand-radiopharmaceutical-manufacturing-in-indiana 2026-08-28T01:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rayzebio-announces-173-million-investment-to-expand-radiopharmaceutical-manufacturing-in-indiana 2026-08-28T01:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/knight-therapeutics-submits-supplemental-application-to-anvisa-for-first-line-minjuvi-tafasitamab-in-dlbcl-and-hgbl 2026-08-28T00:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/knight-therapeutics-submits-supplemental-application-to-anvisa-for-first-line-minjuvi-tafasitamab-in-dlbcl-and-hgbl 2026-08-28T00:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/dolly-parton-offered-to-undergo-experimental-cancer-drug-trials-to-help-future-patients 2026-08-28T00:48:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dolly-parton-offered-to-undergo-experimental-cancer-drug-trials-to-help-future-patients 2026-08-28T00:48:15+00:00 hourly 0.9 https://trial.medpath.com/news/tim-3-identified-as-common-culprit-and-predictive-biomarker-in-severe-bone-infections 2026-08-27T22:54:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tim-3-identified-as-common-culprit-and-predictive-biomarker-in-severe-bone-infections 2026-08-27T22:54:55+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-how-sglt2-inhibitors-improve-failing-heart-function-by-activating-pank1 2026-08-27T22:54:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-how-sglt2-inhibitors-improve-failing-heart-function-by-activating-pank1 2026-08-27T22:54:48+00:00 hourly 0.9 https://trial.medpath.com/news/saic-appoints-14-member-science-panel-as-independent-funding-call-opens 2026-08-27T22:54:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saic-appoints-14-member-science-panel-as-independent-funding-call-opens 2026-08-27T22:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/anthropic-s-model-hardware-standard-lets-ai-agents-autonomously-run-lab-experiments-across-drug-discovery 2026-08-27T21:51:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anthropic-s-model-hardware-standard-lets-ai-agents-autonomously-run-lab-experiments-across-drug-discovery 2026-08-27T21:51:05+00:00 hourly 0.9 https://trial.medpath.com/news/novogene-to-establish-australia-s-first-hospital-co-located-genomics-laboratory-at-cabrini-health 2026-08-27T21:49:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novogene-to-establish-australia-s-first-hospital-co-located-genomics-laboratory-at-cabrini-health 2026-08-27T21:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/karolinska-institutet-temporarily-closes-website-for-technical-maintenance 2026-08-27T21:49:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karolinska-institutet-temporarily-closes-website-for-technical-maintenance 2026-08-27T21:49:35+00:00 hourly 0.9 https://trial.medpath.com/news/primate-specific-alu-mediated-spast-deletion-reveals-a-druggable-zinc-golgi-pathway-in-dementia-related-neurodegeneration 2026-08-27T21:49:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/primate-specific-alu-mediated-spast-deletion-reveals-a-druggable-zinc-golgi-pathway-in-dementia-related-neurodegeneration 2026-08-27T21:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/ph-kurien-s-landmark-nexavar-compulsory-licence-india-s-defining-moment-in-affordable-cancer-care 2026-08-27T21:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ph-kurien-s-landmark-nexavar-compulsory-licence-india-s-defining-moment-in-affordable-cancer-care 2026-08-27T21:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/rectify-pharmaceuticals-unveils-rty-406-an-oral-dual-abcb4-bsep-modulator-for-primary-sclerosing-cholangitis 2026-08-27T21:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rectify-pharmaceuticals-unveils-rty-406-an-oral-dual-abcb4-bsep-modulator-for-primary-sclerosing-cholangitis 2026-08-27T21:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/fred-hutch-launches-15-million-trial-comparing-stem-cell-transplant-vs-non-transplant-therapy-in-older-aml-patients 2026-08-27T20:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fred-hutch-launches-15-million-trial-comparing-stem-cell-transplant-vs-non-transplant-therapy-in-older-aml-patients 2026-08-27T20:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/evonik-expands-lipid-based-drug-delivery-capacity-with-new-gmp-facility-in-vancouver 2026-08-27T20:48:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evonik-expands-lipid-based-drug-delivery-capacity-with-new-gmp-facility-in-vancouver 2026-08-27T20:48:48+00:00 hourly 0.9 https://trial.medpath.com/news/oryon-cell-therapies-appoints-kenny-choi-ph-d-as-chief-technical-officer-to-scale-autologous-neuron-replacement-manufacturing 2026-08-27T19:50:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oryon-cell-therapies-appoints-kenny-choi-ph-d-as-chief-technical-officer-to-scale-autologous-neuron-replacement-manufacturing 2026-08-27T19:50:03+00:00 hourly 0.9 https://trial.medpath.com/news/scalable-stem-cell-method-advances-off-the-shelf-car-t-therapies 2026-08-27T17:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scalable-stem-cell-method-advances-off-the-shelf-car-t-therapies 2026-08-27T17:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/new-ceos-at-gsk-novo-nordisk-and-sanofi-chart-divergent-paths-through-pivotal-transitions 2026-08-27T17:49:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-ceos-at-gsk-novo-nordisk-and-sanofi-chart-divergent-paths-through-pivotal-transitions 2026-08-27T17:49:28+00:00 hourly 0.9